Version: 5.[ADDRESS_253566] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  1  
OTT166 -201 A Phase 2 Randomized, Double -Masked, 
Vehicle- Control led, Multicenter Study to Evaluate the Safety and 
Efficacy of OTT166 Ophthalmic Solution in the Treatment of 
Diabetic Retinopathy (DR)  
 
Protocol Number:  OTT166 -201 
Brief Title: OTT166 in DR 
Version:  5.0 
 
Sponsor Name [CONTACT_1781]:  
OcuTerra Therapeutics, Inc.  
[ADDRESS_253567]  
16th Floor 
[LOCATION_011], MA [ZIP_CODE] 
 
Regulatory Agency Identifier:  
FDA IND:  126944 
 
Study Responsible Medical Lead : 
David Tanzer, MD 
Chief Medical Officer, OcuTerra  
Confidential  
The information  provided in this document  is strictly  confidential  and is intended  solely  for the performance 
of the clinical  investigation.  Reproduction  or disclosure  of this document,  whether in part or in full, to 
parties  not associated  with the clinical  investigation  or its use for any other  purpose  without  the prior  written  
consent  of the Sponsor  is not permitted.  
 
Version: 5.[ADDRESS_253568] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  2 PROTOCOL AMENDMENT SUMMARY OF CHANGES  
Document History  Date  
Amendment 04 (V5.0)  10 October  2023  
Amendment 03 (V4.0)  21 December 2022  
Amendment 02 (V3.0)  14 October 2022  
Amendment 01 (V2.0)  11 May 2022  
Original Protocol (V1.0)  02 March 2022  
 
Amendment 0 4 (V5.0), [ADDRESS_253569] 2023 
A description of important changes in this amendment is provided in  the table below: 
Section # and Name  [CONTACT_11029]  
1.0 Study Synopsis  
2.20.2 Outcome 
Measures  Secondary endpoints updated to include :  
“Proportion of participants developi[INVESTIGATOR_211643] 
24”, “Time to development of PDR worse than mild 
(DRSS 65 and above) or CI- DME”, and “Time to 
rescue therapy for participants who meet objective 
criteria for rescue therapy”.  
“Mean and median step change in DRSS step from 
baseline to Week 24” was removed.   To clarify and further 
define the endpoints . 
1.0 Study Synopsis  
2.9 Exclusion 
Criteria  Exclusion #1 updated to include “and there is a 
normal foveal contour as determined by [CONTACT_211669]”.  To specify the 
exclusion criteria.  
1.0 Study Synopsis  
2.9 Exclusion 
Criteria  Exclusion #[ADDRESS_253570] of medications extended to 
“Liraglutides, Dulaglutides, and Tirzepatides”.  To reflect additional 
medications that are 
exclusionary.  
1.0 Study Synopsis  
2.14.9 Rescue 
Criteria  Added “Development of ASNV”.  To clarify the rescue 
criteria.  
1.[ADDRESS_253571] current 
knowledge.  To align with current 
knowledge of 
background.  
2.14.4 Study Intervention 
Compliance and Adherence  
2.15.1 Schedule of Activities  Updated to clarify “compliance” per protocol and 
“adherence” for the MEMS Cap® use, and to 
emphasize the importance of continuously monitoring 
adherence to ensure participants are taking the correct 
number of prescribed doses.  
“IP adherence review” added to the SoA to ensure 
sites are discussing adherence with participants at 
each study visit and continuously monitoring this 
activity.  To clarify 
“compliance” and 
“adherence”.  
Version: 5.[ADDRESS_253572] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  3 Section # and Name  [CONTACT_11029]  
2.15.1 Schedule of 
Activities  Visit 8 “continue study treatment” in the SoA 
remo ved as this is the end of study visit.  Administrative update.  
2.15.1 Schedule of 
Activities  Footnote “m” added to ensure cornea is assessed at 
the beginning of the visits before dilation.  To ensure cornea is 
not impacted by [CONTACT_211670].  
2.16.[ADDRESS_253573] as “DRSS 65 and 
above” and added “CI -DME” to the list.  
To clarify the 
definition of vision -
threatening 
complication.  
3.2 Appendix 2  ETDRS table updated to be more specific.  To provide specific 
details for each level 
of severity.  
 
Version: 5.[ADDRESS_253574] ...............................................................................................22  
2.4 OTT166 Background .......................................................................................23  
2.5 Previous Clinical Studies .................................................................................25  
2.5.1  OTT166 in DME ..................................................................................25  
2.5.2  OTT166 in nAMD ...............................................................................26  
2.6 Study Design ....................................................................................................26  
2.7 Study Population ..............................................................................................27  
2.8 Inclusion Criteria  .............................................................................................27  
2.9 Exclusi on Criteria  ............................................................................................28  
2.10  Lifestyle Considerations  ..................................................................................30  
2.11  Screen Failures  .................................................................................................30  
2.12  Criteria for Temporarily Delaying Randomization / Study Intervention 
Administration  .................................................................................................30  
2.13  Selection of the Study Eye ...............................................................................31  
2.14  Study Intervention(s) and Concomitant Therapy .............................................31  
2.14.1  Study Intervention  ................................................................................31  
2.14.2  Preparation  / Handling / Storage / Accountability ................................31  
2.14.3  Measures to Minimize Bias: Randomization and Masking  .................32  
2.14.4  Study Intervention  Compliance and Adherence  ...................................32  
2.14.5  Dose  Modification  ................................................................................33  
2.14.6  Stoppi[INVESTIGATOR_1869]  (Study Level)  ..............................................................33  
2.14.7  Continued Access to Study Intervention After the End of the Study ..34  
2.14.8  Concomitant and Prohibited Therapy in the Study Eye.......................34  
2.14.9  Rescue Therapy  ....................................................................................34  
2.14.10  Discontinuation of Study Intervention and Participant Discontinuation / Withdrawal ..............................................................35
 
[IP_ADDRESS]  Permanent Discontinuation  .........................................................35  
[IP_ADDRESS]  Temporary Discontinuation ........................................................35  
Version: 5.[ADDRESS_253575] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  5 2.14.11  Participant Discontinuation / Withdrawal from the Study  ...................[ADDRESS_253576] to Follow-up .................................................................................36  
2.15  Study Assessments and Procedures  .................................................................36  
2.15.1  Schedule of Activities  ..........................................................................38  
2.15.2  Study Activities  ....................................................................................40  
2.15.3  Blood Sampling ...................................................................................40  
2.16  Efficacy Assessments  .......................................................................................40  
2.16.1  Ophthalmology Assessments ...............................................................40  
2.16.2  Color Fundus Photography (CFP) .......................................................[ADDRESS_253577] Corrected Visual Acuity (BCVA) ................................................41  
2.16.4  Fluorescein Angiography (FA)  ............................................................41  
2.16.5  Optical Coherence Tomography (OCT) ..............................................41  
2.16.6  Optical Coherence Tomography Angiography (OCTA) .....................41  
2.16.7  Slit Lamp Biomicroscopy (Anterior and Posterior Segment)  ..............42  
2.16.8  Tonometry (Intraocular Pressure (IOP) Measurement)  .......................42  
2.16.9  Vision -threatening Complications  .......................................................42  
2.16.10  DME and CI- DME  ...............................................................................42  
2.17  Safety Assessments  ..........................................................................................43  
2.17.1  Physical  Examination  ...........................................................................43  
2.17.2  Vital Signs  ............................................................................................43  
2.17.3  Clinical Safety  Laboratory  Assessments  ..............................................43  
2.17.4  Pregnancy Testing  ................................................................................44  
2.18  Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Safety 
Reporting..........................................................................................................[ADDRESS_253578] (AESI) ..........................................46  
2.19  Pharmacoki netics  .............................................................................................46  
2.20  Statistical Considerations  .................................................................................47  
2.20.1  Statistical Hypotheses / Sample Size Determination  ...........................47  
2.20.2  Outcome Measures ...............................................................................47  
2.20.3  Analysis Sets ........................................................................................49  
2.21  Statistical Analyses  ..........................................................................................49  
2.21.1  General Considerations  ........................................................................49  
2.21.2  Efficacy Analyses  ................................................................................50  
Version: 5.[ADDRESS_253579] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  6 [IP_ADDRESS]  Analysis of the Primary Endpoint  ...............................................50  
[IP_ADDRESS]  Analyses of Secondary and Other Efficacy Endpoints ...............51  
2.21.3  Safety Analyses  ....................................................................................52  
2.21.4  Study Drug Exposure ...........................................................................52  
2.21.5  Adverse Events ....................................................................................52  
2.21.6  Vital Signs  ............................................................................................54  
2.21.7  Safety Laboratory Tests  .......................................................................54  
2.21.8  Other Analyses  .....................................................................................54  
2.21.9  Interim Analysis ...................................................................................54  
3 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  .............................................................................................55  
3.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ..........55  
3.1.1  Regulatory and Ethical Considerations  ................................................55  
3.1.2  Financial Disclosure  .............................................................................56  
3.1.3  Informed  Consent Process ....................................................................56  
3.1.4  Data  Protection  .....................................................................................56  
3.1.5  Committees  Structure  ...........................................................................57  
[IP_ADDRESS]  Central Reading Center ...............................................................57  
[IP_ADDRESS]  Steering Committee  ....................................................................57  
3.1.6  Data  quality Assurance  .........................................................................57  
3.1.7  Source Documents................................................................................58  
3.1.8  Study and Site Start and Closure ..........................................................58  
[IP_ADDRESS]  First Act of Recruitment  .............................................................58  
[IP_ADDRESS]  Study / Site Termination  .............................................................59  
3.1.9  Publication  Policy  ................................................................................59  
3.2 Appendix 2: ETDRS Final Retinopathy Severity Scale ..................................61  
3.3 Appendix 3: Clinical Laboratory Tests  ............................................................63  
3.4 Appendix 4: AEs and SAEs: Definitions and Procedures for Recording, Evaluating, Follow -up, and Reporting .............................................................64
 
3.4.1  AE Definition  .......................................................................................64  
3.4.2  Events Meeting the AE Definition .......................................................64  
3.4.3  Events NOT Meeting the AE Definition  .............................................64  
3.4.4  Recording and Follow- up of AE and / or SAE  .....................................66  
3.4.5  Assessment of Intensity  .......................................................................66  
3.4.6  Assessment of Causality  ......................................................................66  
3.4.7  Follow-up of AEs and SAEs ................................................................67  
3.4.8  Reporting of SAEs  ...............................................................................67  
3.5 Appendix 5: Contraceptive Guidance and Collection of Pregnancy Information  ......................................................................................................69
 
3.5.1  Definitions ............................................................................................69  
Version: 5.[ADDRESS_253580] Study: Schedule of Activities (Through 
Week 24 – Primary Endpoint)  ...................................................................38  
Table  2 Analysis Sets ..............................................................................................49  
Table  3 ETDRS  Final  Retinopathy Severity  Scale (for Individual Eyes)  ...............[ADDRESS_253581] OF FIGURES  
Figure 1  RGD‑Binding Integrins Involved in the Pathogenesis of Diabetic Retinopathy ................................................................................................24
 
 
Version: 5.[ADDRESS_253582]  Early Treatment Report Diabetic Retinopathy  
eCRF  Electronic Case Report Form  
EOS  end of study 
FA fluorescein angiography  
FAS full analysis set  
FAZ  foveal avascular zone 
GAT  Goldmann applanation tonometry  
GCP  Good Clinical Practice  
HbA1c  glycosylated hemoglobin  
IB Investigator ’s Brochure  
IC50 half maximal inhibition concentration  
ICF informed consent form 
ICE intercurrent event 
ICH International Council  for Harmonisation  
IEC Independent Ethics Committee  
IOP intraocular pressure  
IRB Institutional Review Board  
Version: 5.[ADDRESS_253583]  optical coherence tomography  
OCTA  optical coherence tomography – angiography  
OU both eyes  
PK pharmacokinetic  
PDR  proliferative diabetic retinopathy  
PRP pan-retinal photocoagulation  
PPS per-protocol set 
PT preferred term 
QID four times daily 
QTL  quality tolerance limit 
SAP statistical analysis plan 
SAE  serious adverse event 
SD standard deviation  
SD-OCT  spectral -domain optical coherence tomography  
SE study eye 
SoA schedule of activities  
SOC  system organ class 
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
TEAE  treatment -emergent adverse event 
TESAE  treatment -emergent serious adverse event 
MV macular volume  
VEGF  vascular endothelial growth factor  
VTC  visually threatening complications  
WHO DD  World Health Organization Drug Dictionary  
YAG  yttrium aluminum garnet  
 
Version: 5.[ADDRESS_253584] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  10 1 STUDY SYNOPSIS  
Name [CONTACT_790]/Company:  OcuTerra Therapeutics, Inc.  
Name [CONTACT_211725]:  OTT166 Ophthalmic Solution (5.0%)  
Title of Study:  OTT166 -201 A Phase 2 Randomized, Double -
Masked, Vehicle -Control led, Multicenter Study to 
Evaluate the Safety and Efficacy of OTT166 
Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR) 
Protocol Number:  OTT166 -201 
Phase of Development:  2 
Study Period:  Up to 24 weeks of follow -up 
Methodology:  
A prospective, randomized, double- masked, vehicle -controlled Phase [ADDRESS_253585] an optimum dosing regimen (frequency) for Phase 3 pi[INVESTIGATOR_6518]. Approximately 210 participants diagnosed with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild 
proliferative diabetic retinopathy ( PDR) and who are treatment naïve (ie,  no prior 
anti-vascular endothelial growth factor [ anti-VEGF ] or laser [focal, grid, pan- retinal 
photocoagulation ( PRP) ] administered) will be randomized 2:2:1:1 into the following 
groups: OTT166 5% twice daily (BID), OTT166 5% four times daily (QID), vehicle control BID, vehicle control QID. Randomization will be stratified by [CONTACT_211671] e (DRSS)  score (47 or 53 or 61B). Participants  with PDR (DRSS 
score 61 B) will be capped at 20% of all randomized participants . Each group will self -
administer one 50- µl eye drop of study solution (frequency as assigned) for 24 weeks. 
Sample size:  
The study will enroll approximately 210 participants randomized as above, approximately 70 participants in each OTT166 treatment group and approximately 35 participants per group into each matching vehicle control group and allowing for around 5% study attrition; this will ensure approximately [ADDRESS_253586] 2 steps from baseline on the DRSS at Week 24, completing 66 participants per group (active treatment BID, QID, combined 
vehicle control) through Week 24 will yield 90% power to demonstrate that the active 
Version: 5.[ADDRESS_253587] (active treatment efficacy ra te minus vehicle control efficacy rate) is at 
least 0.[ADDRESS_253588] 0.06. 
The two OTT166 dose regimens will cover a 2-fold dose range in total daily dose 
(5.0 mg/day to 10.0 mg/day).  
Population:  
The population will be participants with Type 1 or Type 2 diabetes under adequate control as evidenced by [CONTACT_211672] (HbA1c) less than or equal to 12.0% , who show 
typi[INVESTIGATOR_211644] , and diagnosed with moderately severe to severe NPDR or mild 
PDR, as defined by [CONTACT_211673] 47, 53, and 61B, with the PDR population capped at 
no more than 20% of all randomized participants . Baseline Best -Corrected Visual Acuity 
(BCVA) must be ≥ 69 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (Snellen equivalent 20/40) and central subfield thickness (CST) must be ≤ [ADDRESS_253589] be confirmed by [CONTACT_73475].  
Primary Objectives:  Primary Endpoints:  
To characterize the safety of 
topi[INVESTIGATOR_211645]166 in participants with DR  • Proportion of participants who develop treatment-
emergent adverse events (TEAEs) through 
Week  [ADDRESS_253590]  • Proportion of participants who have improved by ≥ 2 steps from baseline at Week 24 as determined by [CONTACT_211674]:  Secondary En dpoints:  
To determine if topi[INVESTIGATOR_211645]166 
will prevent or delay the occurrence of visually threatening complications (VTC), defined as PDR worse than mild and/or anterior segment neovascularization (ASNV) and/or CI- DME (defined below)  
 
To determine if topi[INVESTIGATOR_211645]166 
will prevent or delay the 
occurrence of CI -DME . (CI-DME • Proportion of participants developi[INVESTIGATOR_211646] (DRS S 65 and above) at Week 24 
• Proportion of participants who develop ASNV 
determined by [CONTACT_211675] 24  
• Time to development of PDR worse than mild (DRSS 65 and above) 
• Proportion of participants who develop CI- DME 
at Week 24  
• Time to development of CI- DME  
Version: 5.[ADDRESS_253591]  > 325 µm) • Proportion of participants developi[INVESTIGATOR_211643] 24  
• Time to development of PDR worse than mild (DRSS 65 and above) or CI -DME  
To determine the effect of 
OTT166 on DRSS in participants with moderately severe to severe NPDR and mild PDR treated with 
topi[INVESTIGATOR_211645]166 • Proportion of participants with change in DRSS steps at Week [ADDRESS_253592] worsening or improving by 1, 2, or ≥  3 steps.  
• Proportion of participants with mild PDR (DRSS score 61B) at baseline who regress to NPDR 
(DRSS score ≤ 53) by [CONTACT_10585] [ADDRESS_253593] • Mean and median change in BCVA (ETDRS 
letters) from baseline to Week  24 
• Lines  gained/lost in BCVA (± 5, 10, and 
15 ETDRS letters) at Week 24  
• Mean and median change in area under the curve 
(AUC) for change in BCVA from baseline to Week [ADDRESS_253594] • Mean and median change in CST from baseline to Week 24  
• AUC for change in CST from baseline to [ADDRESS_253595] • Proportion of participants who met the objective rescue criteria as defined in protocol 
Section  
2.14.9. 
• Time to meet  objective rescue therapy  criteria  as 
defined in protocol Section  2.14.9. 
• Time to administration of rescue therapy  
Version: 5.[ADDRESS_253596] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  13 Exploratory Objectives  Exploratory Endpoints  
To evaluate the change in DME in 
participants treated with OTT166  • Change in Macular Volume (MV) from baseline 
to Week 24 for 1, 3, and 6 mm regions 
To assess the effects of treatment 
on anatomic markers other than DRSS and on retinal non-perfusion  • Change in area of retinal non- perfusion from 
baseline to Week 24 seen on widefield fluorescein angiography (FA) 
• Proportion of participants with intact foveal avascular zone (FAZ) seen on widefield FA at Week 24  
• Optical coherence tomography angiography (OCTA) endpoints within the 6 mm area:  
- Change from baseline to Week 24 in FAZ area 
- Change from baseline to Week 24 in non-
perfusion area 
- Change from baseline to Week 24 in vessel caliber  
- Ischemic Index  at W eek 24  compared to 
baseline  
- Proportion of participants with new neovascularization at Week 24 
- Proportion of participants with new intraretinal microvascular anomalies (IRMA) at Week 24 
- Change in vessel density f rom baseline to 
Week 24 in the superficial and deep layers  
Key Inclusion Criteria:  
1. Men or women ≥ [ADDRESS_253597] [DRSS levels 47 or 53], or mild PDR [DRSS level 61 B] NVE < 0.5 
DA in 1  + quadrants], 
confirmed by [CONTACT_73475],  in whom PRP 
and/or anti- VEGF intravitreal 
injection (IVT) can be safely 
deferred for at least 6  months Key Exclusion Criteria:  
1. CST of > [ADDRESS_253598] is ≤ [ADDRESS_253599] (peripheral retinal hole treated with laser is allowed) 
Version: 5.[ADDRESS_253600] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  14 per the Investigator. ( ETDRS 
Report 1991 ). 
2. BCVA ETDRS letter score in 
the study eye of ≥  69 letters 
(approximate Snellen equivalent of 20/40 or better) 
3. Normal foveal contour  
4. Treatment  -naïve (ie, no 
previous anti- VEGF or steroid 
treatment or PRP or laser )  
5. Willing and able to return for all study visits and comply with study-related procedures 
6. Able to adhere to the study dosing requirements 
7. Understands and signs the written informed consent form (ICF)  3. Eyes with DRSS score 61 due to fibrous 
proliferations at disc or fibrous proliferations elsewhere  
a. DRSS score 61 B with NVE only is allowed. 
Any sign of fibrosis proliferation is exclusionary 
4. Any prior systemic anti -VEGF or IVT anti -VEGF 
treatment in the study eye  
5. Any prior intraocular steroid injection in the study eye, inclusive of Iluvien® and Retisert®  
a. History of Ozurdex® and triamcinolone use prior to 12 months before study enrollment is allowed  
6. Current ASNV, vitreous hemorrhage, or tractional retinal detachment visible at the screening assessments in the study eye 
7. Uncontrolled glaucoma or ocular hypertension in the study eye defined as an intraocular pressure (IOP) >  25 millimeter of mercury (mmHg) 
regardless of concomitant treatment with IOP-lowering medications  
8. Hypertension defined as systolic > 180  mmHg or 
> 160 mmHg on 2 consecutive measurements (during the same visit) or diastolic > [ADDRESS_253601] > 12.0% 
10. Renal failure (stage 4 or end -stage), dialysis, or 
history of renal transplant 
11. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspic ion of 
a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or render the participant at high risk for treatment complications 
12. Initiation of intensive insulin treatme nt (a pump 
or multiple daily injections) within 4  months prior 
to randomization or plans to do so in the next 4 months 
Version: 5.[ADDRESS_253602] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  15 13. Epi[INVESTIGATOR_43691], posterior hyaloidal traction, 
and/or vitreomacular traction in the study eye as 
determined to be significant by [CONTACT_737]  
14. Previous pars plana vitrectomy in the study eye 
15. Any intraocular surgery in the study eye within 90 days (3 months) prior to study enrollment 
16. Yttrium Aluminum Garnet (YAG) laser treatment in the study eye within [ADDRESS_253603] 90 days prior to study enrollment and expected to stay on stable dose throughout study participation. Topi[INVESTIGATOR_211647] ±  [ADDRESS_253604] lens use from time of screening throughout the study  
19. Central corneal changes from dry eye that are visually significant and/or Sjogren’s syndrome  
20. Visually significant F uchs endothelial dystrophy 
or other diagnosed conditions of corneal compromise including Anterior Basement Membrane Dystrophy, or any corneal dystrophy affecting central vision (peripheral processes are not exclusionary) 
21. Chronic or recurrent uveitis in the  study eye 
22. Ongoing ocular infection or inflammation in either eye  
23. A history of cataract surgery complicated by [CONTACT_211676] 
24. Congenital eye malformations in the study eye 
25. A history of penetrating ocular trauma in the study eye 
26. Cognitive im pairment that, in the opi[INVESTIGATOR_1070], could compromise compliance with the requirements of the study  
27. Females of childbearing potential (ie, who are not postmenopausal for at least [ADDRESS_253605] 6 weeks prior to Vis it 1 – 
Version: 5.[ADDRESS_253606] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  16 Screening/Randomization) who are lactating, or 
who are pregnant as determined by a positive 
serum pregnancy test at Visit 1 – Screening/ Randomization. Women of childbearing potential must agree to use acceptable methods of birth control throughout the study. 
a. Women who are breastfeeding or who have a positive serum hCG/urine pregnancy test at the screening or B aseline (BL) V isit 
28. Females and males of childbearing potential unwilling or unable to utilize the following acceptable methods of birth control: tubal ligation, transdermal patch, intrauterine devices/systems, oral/implantable/injectable or contraceptives, diaphragm or cervi cal cap with 
spermicide, or vasectomized partner for females; condoms with spermicidal agent and vasectomy for males; or sexual abstinence for males and females  
29. Participation in any other investigational device or drug clinical research study within 12 weeks of Visit 1 – Screening/ Randomization and during the duration of enrollment  
30. Contraindication to the study medications or fluorescein dye  
31. Other ocular pathologies that, in the investigator’s opi[INVESTIGATOR_1649], would interfere with the participant’s vision in the study eye 
32. Ocular media of insufficient quality to obtain fundus photographs, fluorescein angiography, and OCT images in the study eye 
33. Concomitant use of Semaglutide (Wegovy®, Ozempic®, Rybelsus®),Thiazolidinediones (Actos®, Avandia®), Liraglutides (Victoza®, Saxenda®), Dulaglutide (Trulicity®), or Tirzepatide (Mounjaro®) within 12 months prior to Visit 1(allowed if a stable dose has been established fo r at least1 year of use)  
a. Plans to start concomitant use of Semaglutides,Thiazolidinediones, Liraglutides, Dulaglutides, or Tirzepatides during the study duration is exclusionary 
Version: 5.[ADDRESS_253607] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  17 Note: The inclusion and exclusion criteria apply  through study duration for 
non-emergency ocular procedures and surgery.  
Duration of Treatment:  24 weeks  
Designation of Study Eye:  
Only one eye will be designated as the study eye in every participant. For participants who 
meet eligibility criteria in both eyes during the screening phase, the eye with the higher reading center confirmed DRSS should be selected. If both eyes have the same score, the eye with the cle arest lens and ocular media will be selected. If there is no objective basis 
for selecting the study eye, factors such as ocular dominance (better focus ability), other ocular pathology, and participant preference should be considered in making the selection. The final selection will be done by [CONTACT_941] I nvestigator in discussion with the participant at 
baseline and must not be changed during the course of the study. 
The non- study eye is eligible for treatment according to the  standard of care treatments 
through the duration of the study.  
Study procedures/assessments:  
Assessments will be performed  monthly during each clinic visit unless indicated otherwise 
in the Schedule of Activities  (SoA) , and include the following: 
• Adverse event recording 
• Review of concomitant medications  
• Vital signs  
• Physical examination (Screening Visit only)  
• Laboratory testi ng (hematology, blood chemistry, urinalysis, and HbA1c) 
• Pregnancy testing (as applicable)  
• BCVA (ETDRS)  
• Slit-lamp bio- microscopy  
• Ocular surface health [fluorescein stain of the cornea]  
• IOP 
• Indirect ophthalmoscopy/dilated fundus examination 
• Spectral domain OCT (SD-OCT) (central subfield thickness, macular volume, foveal 
contour) at every visit 
Version: 5.[ADDRESS_253608] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  18 • 7-field or 4 -wide field color fundus photography at every visit [optional wide- field if 
available]  
• DRSS scoring, based on 7- field or 4 -wide field photos by [CONTACT_978] [INVESTIGATOR_211648]  
• Fluorescein angiography (FA) (wide field if available) at baseline and end of study 
• OCTA if available (for exploratory endpoints) at baseline and end of study 
• Rescue therapy initiation, per alignment between Investigator and Medical Monitor 
• HbA1c at screening and end of treatment 
• Gonioscopy 
Visit Timeline:  
Screening – V isit 1; Baseline  (BL)  – Visit 2; Week 4 – V isit 3; Week 8 – V isit 4; 
Week  12 – V isit 5; Week  16 – Visit 6; Week 20 – Visit 7; Week 24 – V isit 8 
Rescue Criteria:  
Participants meeting any of the following criteria would qualify for rescue with anti- VEGF 
therapy and/or PRP laser after consultation with the Medical Monitor: 
Objective Rescue Therapy Criteria:  
• Worsening DRSS level to 65 or higher as confirmed by [CONTACT_73475] 
• Development of ASNV 
• Decrease in BCVA of ≥ 10 ETDRS letters from baseline associated with presence of 
new fluid or an increase in fluid in the central subfield compared to baseline at any 
visit 
• Decrease in BCVA of 5 to 9 ETDRS letters from baseline at two consecutive visits 4 weeks apart associated with presence of new fluid or an increase in fluid in the central subfield compared to baseline  
• Increase in CST of ≥ 75 microns from baseline associated with presence of new fluid or an increase in fluid in the central subfield compared to baseline  
 
Subjective Rescue Criteria:  
• Any condition that, in the clinical opi[INVESTIGATOR_689], warrants rescue therapy 
after consultation with the Medical Monitor  
Version: 5.[ADDRESS_253609] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  19 Statistical Analyses:  
Statistical analyses will include tabulations of summary data, inferential analyses, by 
[CONTACT_211677], and figures. 
All statistical tests will be one -sided and will be performed at the 5% level of significance, 
unless otherwise stated. The vehicle control group will be combined for all efficacy  
analyses and two -sided 90% confidence intervals will be presented. Frequency counts (n 
and percentages) will be made for each q ualitative variable. Descriptive statistics (n, mean, 
standard deviation [ SD], median, minimum, and maximum) will be calculated for each 
quantitative variable, unless otherwise stated. All data will be summarized by [CONTACT_6490]. 
The baseline value for analysis and reporting will be based on the last (non- missing) 
measurement before dosing on Day 1. Comparison of the primary endpoint will be made between each dose group and the 
combined vehicle control group using a Mantel- Haenszel (MH) test of the diffe rence in 
2 proportions stratified by [CONTACT_22055] (BL DRSS score 47 or 53 or 61B ). The estimated MH risk difference will be summarized along with the 2 -sided 
90% CI using MH stratum weights and the Sato variance estimator. The primary efficacy analysis will be performed on the ITT, while the PP set will be used as supplementary analyses.  
All secondary endpoint analyses will be performed on the ITT analysis set. The secondary endpoints involving proportions of participants will be analyzed using the same approach (MH test) as described for the primary efficacy analysis. Time to event secondary endpoints will be analyzed using a stratified log-rank test adjusting for the randomization stratification factor.  Continuous secondary endpo ints involving change from BL will be 
analyzed using an analysis of covariance (ANCOVA) model with BL measurement of the variable as a covariate and treatment group and the randomization stratification factor as fixed factors. The pair- wise comparisons of each OTT166 dose group versus combined 
vehicle control will be done in the ANCOVA model. Two-sided 90% confidence intervals for the difference of each OTT166 dose group minus combined vehicle control will be calculated.  
All safety summaries and analyses will be based on the Safety Analysis Set by [CONTACT_1570] (i.e., vehicle control doses (5% BID, 5% QID), vehicle control combined, active OTT166 doses (5% BID, 5% QID), and OTT166 combined). and overall. AEs will be 
coded using MedDRA and summarized by [CONTACT_9313] (SOC) and preferred term (PT). Analysis and reporting for AEs will be based on TEAEs. A TEAE is defined as an AE occurring (onset date/time) at the time of or after dosing on Day 1. Summaries of TEAEs by [CONTACT_1570], SOC, and PT will include the following: All TEAEs, ocular  
TEAEs and TESAEs in the study eye, ocular TEAE s and TE SAEs in the fellow eye, 
non-ocular  TEAE s and TESAEs, all TESAEs, TEAEs and TESAEs leading to 
Version: 5.[ADDRESS_253610] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  20 discontinuation of study drug , TEAEs and TESAEs leading to discontinuation of study , 
drug- related TEAEs  and TESAEs , TEAEs by [CONTACT_2236], AESIs. 
Version: 5.[ADDRESS_253611]. 
OTT166 is a representative from a new class of drugs ( ie, a topi[INVESTIGATOR_211649]). It is being developed for treatment of DR. The study is intended to 
show in particular t hat OTT166:  
• Is overall safe and well tolerated  
• Prevents progression of DR  
• Prevents VTCs and/or CI- DME  
• Reverses retinal changes attributed to DR  
• Maintains visual acuity  
 
2.2 Study Objectives  
The primary objectives for this study are: 
• To characterize the safety of topi[INVESTIGATOR_211645]166 in participants with DR 
• To characterize the efficacy of topi[INVESTIGATOR_211645]166 in participants with DR  
 The secondary objectives of this study are: 
• To determine if topi[INVESTIGATOR_211645]166 will prevent or delay the occurrence of VTC, defined as 
PDR worse than mild and/or ASNV  and/or CI_DME 
• To determine if topi[INVESTIGATOR_211645]166 will prevent or delay the occurrence of CI- DME  
• To determine the effect of OTT166 on DRSS in participants with moderately severe to severe NPDR and mild PDR treated with topi[INVESTIGATOR_211645]166  
• To determine the effect of OTT166 on BCVA in participants with moderately severe to severe NPDR and mild PDR  
• To determine the effect of OTT166 on central subfield thickness in participants with moderately severe to severe NPDR and mild PDR  
Version: 5.[ADDRESS_253612] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  22 • To determine the effect of OTT166 on the need for rescue therapy in participants with 
moderately severe to severe NPDR and mild PDR  
 
The exploratory objectives of this study are: 
• To evaluate the change in DME in participants treated with OTT166  
• To assess the effects of treatment on  anatomic markers other than DRSS and on retinal 
non-perfusion  
 2.[ADDRESS_253613] has a multifactorial origin and is caused by [CONTACT_157710]-induced oxidative stress, 
hypoxia, pericyte loss, endothelial cell loss, leu kostasis, and inflammation . It leads to a 
breakdown of the blood- retinal barrier. There is extensive evidence that angiogenic cytokines 
(eg, VEGF) and inflammatory cytokines are involved in the development of DR. DR is categorized based on the presence of vascular and vascular associated lesions and the 
absence (in NPDR)  or presence (in PDR) of neovascularization. Earlier  clinical features of 
DR include microaneurysm, hemorrhage, cotton wool spots , hard exudates  and IRMAs. As 
the severity of DR progresses, capi[INVESTIGATOR_211650]-perfusion leads to retinal  ischemia . This induces 
an upregulation of pro- angiogenic and pro- inflammatory cytokines , leading  to proliferation 
of aberrant  retinal vasculature. When left untreated, these new, fenestrated , brittle and leaky 
vessels extend and grow and result in vitreous hemorrhage and/or exudation. This is 
associated with the formation of gliosis and fibrous tissue  formation . These scars contract 
and can result in tractional retinal detachment and loss of vision  (Lechner 2017, 
Cheung 2010, Wang 2018). 
Treatment options for moderately severe and severe NPDR and PDR include PRP, 
anti-VEGF agents , and vitrectomy for PDR ( Wang 2018). PRP has been the gold standard for 
> [ADDRESS_253614] Study has shown that PRP  reduces the risk of 
severe vision loss by [CONTACT_46431] 50% ( Aiello et al. 1973). However, PR P is destructive and causes 
permanent peripheral vision loss  that may interfere with driving and impair night vision, 
color vision , and contrast sensitivity. It may also  exacerbate DME ( Brucker 2009, 
Ferris  1987 ). Anti -VEGF therapi[INVESTIGATOR_211651], regardless of severity , but 
they can require monthly intravitreal injections, with the continuous risk of serious side effects , such as endophthalmitis or retinal detachment , and the inconvenience of traveling to 
a retina specialist office for every injection . Thus, there is an unmet clinical need for 
non-invasive efficient treatment options.  
OTT166  is intended to address the current limitations in the treatment of D R. As outlined 
above, anti -VEGF treatment requires IVT  every [ADDRESS_253615] represent a significant burden to participants , particularly 
for D R participants, many of whom are of working age. An alternative mode of drug 
administration, particularly topi[INVESTIGATOR_211652], represents a very attractive treatment option.  
Version: 5.[ADDRESS_253616] on the abili ty for the 
treatment to reach  the back of the eye. Activity of OTT166  in VEGF -driven models appears 
similar to anti-VEGF biologics. Moreover, OTT166  also blocks angiogenic signaling driven 
by [CONTACT_211678] (platelet -derived and fibroblast growth fac tor), so clinical efficacy 
could exceed that of marketed drugs that only target VEGF. 
Based on the pre- clinical information, it is expected that the benefits of OTT166  outweigh 
the risks of its use.  
2.[ADDRESS_253617] is caused  by [CONTACT_211679] -age population. The disease starts with 
the formation of microaneurysms and progresses to hemorrhages and neovascularization  of 
the retina and vitreous. At any point along this continuum, vessels can leak fluid into the 
macula, causing diabetic macular edema (DME) and consequently cause loss of eyesight, particularly if the fluid accumulates in the center of the macula. Patients with mild or moderate DR have an approximately 23% chance of progressing to severe disease over 5 years and an approximately 60% chance of developi[INVESTIGATOR_211653] ( Cheung 2010, Fer ris 1987, 
Wang 2018).  
Integrins are proteins found on the surface of cells that help them attach to, and communicate 
with nearby [INVESTIGATOR_100372], and play an important role in cell growth, cell movement, and other cell 
functions. Integrins are comprised of an α  subunit and a β  subunit and [ADDRESS_253618] been identified. Integrins that recognize ligands with an RGD sequence, called 
RGD‑binding integrins, play key role s in the [ADDRESS_253619]: vascular leakage, 
neovascularization, inflammation, and fibrosis ( Figure 1). Expression of high levels of the 
integrin α
vβ3 and α vβ5 in human retinal membranes from patients with proliferative DR have 
been reported. 
Version: 5.[ADDRESS_253620] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  24 Figure  1 RGD‑Binding Integrins Involved in the Pathogenesis of Diabetic 
Retinopathy  
 
RGD = arginine -glycine -aspartic acid.  
Source: Van Hove I, Hu TT, Beets K, et al. Targeting RGD -binding integrins as an integrative therapy for 
diabetic retinopathy and neovascular age -related macular degeneration. Prog Retin Eye Res.  2021;85:100966.  
 
Small molec ule inhibitors (antagonists) of RGD -binding integrins have shown efficacy in 
animal models of retinal neovascularization when administered by [CONTACT_22666], 
intraperitoneal injection, periocular injection, or topi[INVESTIGATOR_897]. A reported RGD -binding inte grin 
inhibitor, risuteganib (Allegro Ophthalmics), that is delivered by [CONTACT_63385] (IVT) has completed a Phase 2b study for the treatment of DME (ClinicalTrials.gov: [STUDY_ID_REMOVED]). This integrin inhibitor has been studied in more than 200 participants and has shown efficacy similar to anti -VEGF (vascular endothelial growth factor) with a reduced 
number of injections. Another small molecule RGD‑binding integrin inhibitor, THR -687 
(Oxurion NV), administered by [CONTACT_211680], has recently been studied in a si ngle‑dose‑escalation 
Phase 1 trial. The Phase 2 INTEGRAL trial data showed THR‑687 to be safe and well tolerated with no serious adverse events (SAEs) and none of the patients required rescue medication through Month 3, however, there was insufficient evidence of efficacy on the key endpoints (best corrected visual acuity [BCVA] and central subfield thickness). As a result, Oxurion NV has decided not to continue the clinical development of THR-687. No topi[INVESTIGATOR_211654]‑binding integrin inhibitor, o ther than OTT166, has advanced into clinical 
testing to date. 
OTT166 is a potent and selective small molecule RGD‑binding integrin inhibitor with a 
balance of physiochemical properties to allow it to distribute to the retina in high concentrations after to pi[INVESTIGATOR_78086]. The company discovered OTT166 by [CONTACT_211681]-depth knowledge of the impact of incorporating fluorine substituents into small molecules 
drugs to alter their chemical and pharmacological properties. MK-0429, the predicate molecule to OT T166, was tested in clinical trials for the treatment of osteoporosis in high 
oral doses and was found to be safe and well tolerated but was not further developed for commercial reasons. OcuTerra demonstrated that while MK -0429 does not distribute to the 
back of the eye after topi[INVESTIGATOR_78086], addition of fluorine substituents in specific positions on MK -0429 resulted in OTT166 with high potency and selectivity for 
Fibrosis 
Version: 5.[ADDRESS_253621] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  25 RGD-binding integrins and OTT166 does distribute to the back of the eye after 
administration as an eye drop. 
2.5 Previous Clinical Studies  
OTT166 topi[INVESTIGATOR_211655] 2 Phase 1b clinical trials, 1 in 
participants with center -involving (CI) DME and the other in participants with nAMD. Each 
study enrolled 44 participants who were treated with OTT166 eye drops twice daily (BID) for 28 days and then followed for an additional 28 days after concluding treatment. There were 2 dose groups in each study: 2.5% (1.25 mg/eye) BID and 5% (2.5 mg/eye) BID; participants were randomiz ed 1:1 to the 2 groups. The primary objective of each study was to 
determine safety and tolerability of the study treatments. The safety evaluations included adverse event (AE) reporting, intraocular pressure (IOP) and BCVA measurements, slit -lamp 
and fundus examinations, and fluorescein angiography (FA). Exploratory efficacy (ie, evidence of biological activity) was assessed by [CONTACT_109793] (BL) in retinal thickness parameters measured by [CONTACT_211682] -domain optical coherence tomography and 
change from BL in BCVA.  
2.5.[ADDRESS_253622] study indicate that both doses of OTT166  (1.25 and 2.5 mg/eye BID) 
are safe and well tolerated in adult participants  with CI -DME. Six participants , 5 (22.7%) in 
the OTT166  1.25 mg/eye group and 1 (4.5%) in the OTT166  2.5 mg/eye group, had a serious 
TEAE, but all were non-ocular in nature and unrelated to study drug. Six participants  
experienced ocular TEAEs in the study eye, 2 (9.1%) in the OTT166  1.25 mg/eye group and 
4 (18.2%) in the OTT166  2.5 mg/eye group. All the ocular TEAEs in the study eye were mild 
in intensity. One event, ocular hyperemia, was considered possibly drug related. 
One participant  (OTT166  1.25 mg/eye) was discontinued from study drug due to an AE 
(hypersensitivity [verbat im: whole body allergic reaction/itching]). Given the onset and 
resolution pattern of the event, the i nvestigator reported the event as probably related to study 
drug. Mean changes from BL  in IOP were no minal in both treatment groups throughout the study. 
There were no TEAEs of ocular hypertension or increased IOP. None of the participants  had 
a clinically relevant change from BL  in the study eye in the slit-lamp, dilated fundoscopy, or 
FA results . 
Four participants received rescue treatment during the 28 -day follow -up period, none during 
the treatment phase. None of the 4 participants  rescued during the recovery phase met the 
rescue criteria.  
There were insignificant changes in the exploratory efficacy measures, change in central 
retinal thickness from BL, and change in BCVA from BL , on a group mean basis; however, 
there was  a subset of participants  that showed significant improvement by [CONTACT_211683] 
a panel of [ADDRESS_253623] scans. Applying their expert 
assessment to the review of the scans of every participant, they determined there were 
Version: 5.[ADDRESS_253624] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  26 14 participants  who  showed evidence of response ( ie, biological activity ), constituting 37% 
of the completed participants  in the study. 
2.5.2 OTT166  in nAMD  
The results of the second study indicate that both doses of OTT166  (1.25 and 2.5 mg/eye 
BID) are safe and well tolerated in adult participants  with nAMD. One participant  (OTT166  
2.5 mg/eye group) had a serious TEAE; the event was non- ocular in nature (peripheral artery 
thrombosis) and not considered related to study drug. In terms of ocular events in the study 
eye, 4 participants , 1 (4.3%) in the OTT166  1.25 mg/eye group and 3 (14.3%) in the OTT166  
2.5 mg/eye group, had a total of 1 and 3 ocular TEAEs, respectively. None of the participants  
had > 1 ocular TEAE in the study eye during the study. All the ocular TEAEs in the study eye were mild or moderate in intensity. One participant ( OTT166  2.5 mg/eye group) had an 
ocular TEAE, dry eye, that was possibly related to study drug. 
Two participants  (both in the OTT166  2.5 mg/eye group) were discontinued from study drug 
due to an AE; these events were headache and retinal hemorrhage in the study eye 
(1 particip ant each). The retinal hemorrhage in the study eye was considered by [CONTACT_211684]. 
Throughout the study, mean changes from BL in IOP were nominal in each treatment group. 
Few slit lamp abnormalities were observed in the study eye during the study, regardless of 
treatment group. Two participants  had a worsening in opacity status in both the study and 
non-study eyes. There were no clinically relevant shifts from normal to abnormal in the fundus examination findings. 
Ten participants  were rescued by [CONTACT_207026]-VEGF drug, 2 during the 
treatment phase and 8 during the follow-up phase of the study, although the criteria for 
rescue were not met in any of the cases.  
There were insignificant changes in the exploratory efficacy measures, change in central 
retinal thickness from BL, and change in BCVA from BL, on a group mean basis; however, 
there was a subset of participants that showed significant improvement by [CONTACT_211683] 
a panel of [ADDRESS_253625] scans. The retina specialists determined that there were 8  participants (19.5%) in the PP population who showed evidence 
of response (ie, biological activity).  
Additional details about the clinical data are provided in the IB.  
2.[ADDRESS_253626] an optimum dosing regimen (frequency) for Phase  [ADDRESS_253627] and who are treatment naïve (ie, no prior anti-VEGF or laser [focal, grid, PRP] administered) will be randomized 2:2:1:1 into the 
following groups: OTT166 5% BID, OTT166 5% QID , vehicle control BID, or vehic le 
control QID. Randomization will be stratified by [CONTACT_211685] (47  or 53 or 61B). 
Participants  with PDR (DRSS score 61 B) will be capped at 20% of all randomized 
Version: 5.[ADDRESS_253628] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  27 participants . Each group will self- administer one 50 -microliter  (µL) eye drop of study 
solution (frequency as assigned) for [ADDRESS_253629] ( participants with mild PDR will be capped at 20% of all randomized 
participants) , as defined by [CONTACT_211673] 47, 53, and 61B. Participants  may have fluid in 
the macula with BCVA of ≥  69 ETDRS letters (Snellen equivalent 20/40) and CST of 
≤ [ADDRESS_253630] anomalies that interfere with  
protocol -required examinations are excluded. 
Prospective approval of protocol deviations to recruitment and enrollment criteria,  also 
known as protocol waivers or exemptions, is not permitted.  
2.8 Inclusion C riteria  
Participants are eligible to be included in the study only if all the following criteria apply:  
1. Men or women ≥  [ADDRESS_253631] [DRSS levels 47 or 53], or mild PDR [DRSS 
level 61B] NVE  < 0.5 DA in 1 + quadrants], in whom PRP and/or anti- VEGF IVT 
can be safely deferred for at least 6 months per  the Investigator ( ETDRS report 1991 ). 
2. BCVA ETDRS letter score in the study eye of ≥  69 letters (approximate Snellen 
equivalent of 20/40 or better)  
3. Normal foveal contour  
4. Treatment naïve (ie, no previous anti- VEGF or steroid treatment or PRP or laser) 
5. Willing and able to return for all study visits and comply with study- related 
procedures 
6. Able to adhere to the study dosing requirements 
7. Understands and signs the written ICF 
 
Version: 5.[ADDRESS_253632] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  28 2.9 Exclusion C riteria  
Participants are excluded from the study  if any of the following criteria apply:  
1. CST of > [ADDRESS_253633] is ≤[ADDRESS_253634] (peripheral retinal hole treated with laser is allowed) 
3. Eyes with DRSS sco re 61 with fibrous proliferations at disc or fibrous proliferations 
elsewhere  
a. DRSS score 61 B with NVE only is allowed. Any sign of fibrosis proliferation is 
exclusionary 
4. Any prior systemic anti- VEGF treatment or IVT anti -VEGF treatment in the study 
eye 
5. Any prior intraocular steroid injection in the study eye, inclusive of Iluvien® and Retisert®  
a. History of Ozurdex® and triamcinolone use prior to 12 months before study enrollment is allowed  
6. Current ASNV, vitreous hemorrhage, or tractional retinal detachment visible at the screening assessments in the study eye 
7. Uncontrolled glaucoma or ocular hypertension in the study eye defined as an IOP > 25 mmHg regardless of concomitant treatment with IOP -lowering medications  
8. Hypertension defined as systolic > 180 mmHg or > 160 mmHg on 2 consecutive measurements (during the same visit) or diastolic > [ADDRESS_253635] > 12.0% 
10. Renal failure (stage 4 or end -stage),  dialysis, or history of renal transplant 
11. History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspi[INVESTIGATOR_1884] a disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or render the particip ant at high risk for treatment 
complications 
12. Initiation of intensive insulin treatment (a pump or multiple daily injections) within 4 months prior to randomization or plans to do so in the next 4 months 
13. Epi[INVESTIGATOR_43691], posterior hyaloidal traction, and/or vitreomacular traction in the study eye as determined to be significant by [CONTACT_737] 
14. Previous pars plana vitrectomy in the study eye 
Version: 5.[ADDRESS_253636] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  29 15. Any intraocular surgery in the study eye within 90 days (3 months) prior to study 
enrollment  
16. YAG laser treatmen t in the study eye within [ADDRESS_253637] 90 days prior to study enrollment and expected to stay on stable dose throughout study participation. Topi[INVESTIGATOR_211656] ± [ADDRESS_253638] lens use from time of screening throughout the study  
19. Central corneal changes from dry eye that are visually significant and/or Sjogren’s syndrome 
20. Visually significant Fuchs endothelial dystrophy or other diagnosed conditions of corneal compromise including Anterior Basement Membrane Dystrophy, or any corneal dystrophy affecting central vision (peripheral processes are not exclusionary)  
21. Chronic or recurrent uveitis in the study eye 
22. Ongoing ocular infection or inflammation in either eye 
23. A history of cataract surgery complicated by [CONTACT_211676] 
24. Congenital eye malformations in the study eye 
25. A history of penetrating ocular trauma in the study eye 
26. Cognitive impairment that, in the opi[INVESTIGATOR_871], could compromise compliance with the requirements of the study  
27. Females of childbearing pot ential (ie, who are not postmenopausal for at least [ADDRESS_253639] 6 weeks prior to Visit 1 – Screening/Randomization) who are lactating, or who are pregnant as determined by a positive serum pregnancy test at Visit 1 – Screening /Randomization. Women of childbearing potential must 
agree to use acceptable methods of birth control throughout the study  
a. Women who are breastfeeding or who have a positive serum hCG/urine pregnancy test at the screening or BL  Visit 
28. Females and males of childbearing potential unwilling or unable to utilize the following acceptable methods of birth control: tubal ligation, transdermal patch, intrauterine devices/systems, oral/implantable/injectable or contraceptives, diaphragm or cervi cal cap with spermicide, or vasectomized partner for females; condoms with 
spermicidal agent and vasectomy for males; or sexual abstinence for males and females  
29. Participation in any other investigational device or drug clinical research study within 12 wee ks of Visit 1 – Screening/Randomization and during the duration of enrollment 
30. Contraindication to the study medications or fluorescein dye  
31. Other ocular pathologies that, in the investigator’s opi[INVESTIGATOR_1649], would interfere with the participant ’s vision in the study eye 
Version: 5.[ADDRESS_253640] images in the study eye 
33. Concomitant use of Semaglutide (Wegovy®, Ozempic®, Rybelsus®), Thiazolidinediones (Actos®, Avandia®), Liraglutides (Victoza® , Saxenda®), 
Dulaglutide (Trulicity®), or Tirzepatide (Mounjaro®) within 12 months prior to Visit 1 (allowed if a stable dose has been established for at least 1 year of use)  
a. Plans to start concomitant use of Semaglutide , Thiazolidinediones, Liraglutides, 
Dulaglutides, or Tirzepatides during the study duration is exclusionary 
 
2.10 Lifestyle C onsiderations  
No study specific lifestyle restrictions  are required. Participation in this study does not 
require modifications of lifestyle.  Participants should follow their usual lifestyle,  as part of 
their diabetes  management plan. 
2.11 Screen F ailures 
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently assigned to study intervention. A minimal set of screen failure  
information  is required  to ensure transparent reporting  of screen  failure  participants  to meet 
the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authorities.  Minimal information includes demography, 
screen  failure  details, and eligibility  criteria.  
Individuals who do not meet the criteria for participation in this study (screen failure) may 
only be rescreened  once. In  any case, the Inves tigator must ensure that the repeated  screening  
procedures do not expose the participant  to an unjustifiable health risk.  For re-screening, the 
participant must re -sign the ICF, even if it was not changed after the participant's previous  
screening.  
Rescreened participants will be assigned a new participant number.  
In case of abnormal or implausible results, which may be caused by [CONTACT_211686],  
short -term treatable conditions, other temporary  health  disorders  (eg, acute  infection,  
laboratory  changes, blood pressure outside defined  range), or inappropriate circumstances 
(eg, inadequate rest when required, hemolysis) , the investigator may  decide to repeat  the 
respective screening  parameter(s)  twice  without rescreening (within 21 days). 
2.12 Criteria for Temporarily Delaying R andomization / S tudy I ntervention 
Administration  
If a participant is otherwise eligible,  the participant’s study intervention may be postponed 
to allow acute intercurrent conditions to resolve.  Under these  circumstances,  the screening 
period may be extended to 6 weeks upon discussion with the medical monitor . 
Version: 5.[ADDRESS_253641] lens and ocular  media  will be selected.  If there  is no objective basis  for 
selecting  the study eye, factors such  as ocular dominance (better focus ability),  other ocular 
pathology, and participant preference should be considered  in making the selection. The final 
selection will be performed and documented by [CONTACT_211687]. 
The non- study eye is eligible for treatment according to the standard of care treatments 
through the duration of the study.  
2.14 Study I ntervention(s) and C oncomitant T herapy  
Study intervention is defined as any investigational intervention(s), marketed product(s), 
vehicle control , or medical device(s) intended to be administered to a study participant , 
according to the study protocol . 
2.14.1 Study  Intervention  
In this study, 5% OTT166  ophthalmic solution or vehicle control , will be given to the 
participants  who will self-administer one 50-µL eye drop of study solution at the prescribed 
frequency based on randomization, for [ADDRESS_253642] (participants  with mild PDR will be 
capped at 20% of all randomized participants ) and who are treatment naïve (ie, no prior 
anti-VEGF or laser [focal, grid, PRP] administered) will be randomized 2:2:1:1 into the 
following groups: OTT166 5% BID (5.0 mg/day),OTT166 5% QID ( 10 mg/day), vehicle 
control BID, or vehicle control QID . Randomization will be stratified by [CONTACT_211688] (47 or 53 or 61B ). 
Eye dropper bottles  containing active treatment of OTT166, and corresponding vehicle 
control, are identical in appearance (size,  color, shape)  and associated with a unique number . 
Eye dropper bottles will be dispensed at the study visits summarized in the SoA 
(Section  2.15.1). Returned eye dropper bottles should not be re-dispensed to the participants. 
2.14.2 Preparation / H andling  / Storage / Accountability 
The investigator or designee must confirm appropriate  temperature  conditions have been 
maintained during transit for all eye dropper bottles  received and any  discrepancies are 
reported and resolved before use of the eye dropper bottle. 
Only  participants randomized in the study may receive eye dropper bottles, and only 
authorized site staff may  supply the eye dropper bottles . All eye dropper bottles must be 
stored in a secure, environmentally controlled,  and monitored  (manual or automated) area in 
Version: 5.[ADDRESS_253643] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  32 accordance with the labeled  storage conditions with access limited  to the investigator and 
authorized site staff.  
The investigator or the head of the institution (where applicable) is responsible for eye 
dropper bottle accountability,  reconciliation, and record maintenance ( ie, receipt,  
reconciliation,  and final disposition records). Drug  receipt,  reconciliation , and destr uction 
information  on the  study sites will be captured in the interactive web response system 
(IWRS ). 
Further guidance and information for the final disposition of unused eye dropper bottles are 
provided in the Investigator Site File.  
2.14.3 Measures to M inimize Bias: Randomization and Masking 
All participants will be centrally  assigned to randomized study intervention using IWRS.  
Participants will be randomized 2:2:1:1 into the following groups: OTT166 5% twice daily (BID), OTT166 5% four times daily (QID), vehic le control BID, vehicle control QID. 
Randomization will be stratified by  [CONTACT_211685] (47 or 53 or 61B). Participants  with PDR 
(DRSS score 61 B) will be capped at 20% of all randomized participants . 
The participant and the clinical assessor will be masked to the treatment group / dose . 
The IWRS  will be programmed with instructions  on how to break/ unmask a participant’s  
randomized treatment.  In case of an emergency, the investigator has the responsibility for 
determining if unmasking of a participant’s  intervention  assignment  is warranted. If the  
investigator is unavailable, and a treating physician not associated with the study requests  
emergency  unmasking, the emergency unmasking requests are forwarded to the emergency  
medical advice 24 -hour/7-day service.  Participant safety  must always be the first  
consideration in making such a determination. If the investigator decides that unmasking is  
warranted, the investigator should make every effort to contact [CONTACT_44686] m onitor prior to 
unmasking a participant’s intervention assignment , unless this could delay emergency  
treatment of the participant.  If a participant’s  intervention  assignment  is unmasked, the 
sponsor must be  notified within [ADDRESS_253644] be  recorded in the source documentation and case report form,  as 
applicable. 
2.14.4 Study  Intervention  Compliance and Adherence  
The clinical investigation uses the Medication Event Monitoring System (MEMS®, 
AARDEX Group, Belgium) during the complete study follow-up period to automatically compi[INVESTIGATOR_211657]. Study medication will be provided to the participants in dropper bottles which should be placed in the MEMS® Cap and bottle system when in use for the MEMS Cap ® to  electronically record the date and time of each 
opening of the medication container. Site personnel will dispense at the baseline v isit and 
then read the MEMS® Caps at each clinic visit using the MEMS Adherence Software (MEMS AS®). The purpose of using the MEMS® is to monitor the participant’s medication intake behavior and related adherence metrics longitudinally in the participant’s  home 
Version: 5.[ADDRESS_253645] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  33 environment during the cl inical investigation. Adherence is calculated in the MEMS AS® 
dashboard and is a feedback tool for sites to intervene when participants deviate from the 
dosing regimen. When a participant deviates from the dosing regimen (i.e., overdoses, underdoses, missed data transfer), the dashboard displays suboptimal adherence or absence of data transfer, and an email is sent to notify the applicable site to intervene. This intervention should be properly documented in the patient dashboard to indicate what type of intervention was needed (e.g., retraining on dosing adherence, retraining on MEMS ® Cap use, retraining on MEMS ® app, etc.). Adherence to study medication should be monitored 
continuously by [CONTACT_211689].  
Compliance is calculated per protocol and is the number of doses taken divided by [CONTACT_211690]. Compliance will be calculated for the final analysis and will be 
determined monthly and overall, through W24. No n-compliance is defined as a dosing record 
of < 75% of the expected number of dosing events, based on the participants’ dosing schedule prescribed at randomization.  
A record of the quantity of bottles dispensed to and administered by [CONTACT_21444]. Intervention start and stop dates, including dates for intervention delays and/or missed doses, will also be  
recorded.  
IWRS will be used for drug accountability on a participant  basis. Drug returns, 
reconciliation , and destruction information will be captured in the  IWRS.  
Taken together, these measures  are deemed appropriate to support participants’ adherence 
and to detect participants who  are systematically  non- adherent  in the opi[INVESTIGATOR_1070]. 
2.14.5 Dose  Modification 
The doses to be administered  are 5% OTT166  (or vehicle control ) either BID or QID . 
No dose modification is planned. 2.14.6 Stoppi[INVESTIGATOR_007] R ules (Study Level)  
The following criteria result in an immediate stop of dosing and will result in a temporary 
halt of the study: 
Any relevant information, from this trial or from outside of this trial, indicating a relevant 
deterioration of the benefit- risk ratio. In particular, consistently observed serious adverse 
events ( SAEs ) or severe drug -related AEs will be thoroughly assessed  by [CONTACT_211691]. 
Resuming the trial after a temporary halt requires an approved substantial amendment. For discontinuation of study intervention for individual study participants, see Section  2.14.10. 
Version: 5.[ADDRESS_253646] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  34 2.14.7 Continued A ccess to S tudy I ntervention A fter the End of the S tudy 
No treatment with study  medication  will be provided after the end of the planned 24- week  
treatment period or after early  withdrawal of treatment.  
2.14.8 Concomitant and Prohibited T herapy in the Study Eye  
No other ocular topi[INVESTIGATOR_191817] (eye drops) should be taken during the study unless prescribed 
by [CONTACT_211692] m edical monitor. If 
topi[INVESTIGATOR_8588] (eye drops) is prescribed , the application of such therapy should not occur 
within 10 minutes (before or after) of instillation of study therapy. Other approved or 
investigational therapi[INVESTIGATOR_211658] (ie,  oral, topi[INVESTIGATOR_2855] , and/or intravitreal injected drugs 
like steroids or anti -VEGFs ) are not permitted, unless applied as rescue therapy 
(Section  2.14.9). Such  intake  is to be recorded  (see below). Contact [CONTACT_211693]. If participant has current contact 
[CONTACT_211694] , contact [CONTACT_211695], and a 14 day 
ocular surface stabilization period is needed between screening and baseline. 
Concomitant medications are to be recorded in the eCRF . 
The medical  monitor should be contact[CONTACT_211696]. 
2.14.9 Rescue Therapy 
Participants  meeting any of the following criteria would qualify for rescue with anti- VEGF 
therapy and/or PRP laser after consultation with the m edical monitor: 
Objective Rescue Therapy Criteria:  
• Worsening DRSS level to 65 or higher as confirmed by [CONTACT_73475] 
• Development of ASNV  
• Decrease in BCVA of ≥ 10 ETDRS letters from BL associated with presence of new fluid 
or an increase in fluid in the central subfield compared to baseline at any visit  
• Decrease in BCVA of 5 to 9 ETDRS letters from BL at two consecutive visits 4 week s 
apart associated with presence of new fluid or an increase in fluid in the central subfield 
compared to baseline  
• Increase in CST of ≥ 75 microns from BL associated with presence of new fluid or an 
increase in fluid in the central subfield compared to baseline  
 
Subjective Rescue Criteria:  
• Any other condition that, in the clinical opi[INVESTIGATOR_871], warrants rescue 
therapy after consultation with the medical monitor 
Version: 5.[ADDRESS_253647] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  35 2.14.10 Discontinuation of S tudy I ntervention and P articipant D iscontinuation  / 
Withdrawal 
[IP_ADDRESS] Permanen t Discontinuation 
In rare instances,  it may  be necessary  for a participant to permanently discontinue  (definitive  
discontinuation) study intervention. If  study intervention is  permanently  discontinued, the 
participant may remain in the study for continued assessment of safety and efficacy  
outcomes. 
Unscheduled visits may be performed as deemed appropriate by [CONTACT_093], in 
particular, in case of withdrawal due to an AE . 
Participants must be withdrawn from the  study intervention for  any of the following reasons:  
• If rescue therapy has been initiated 
• Safety concerns for a participant by [CONTACT_8893] 
• Vision threatening complication meeting rescue criteria and/or progression to worse than 
mild PDR with DRSS > 61  
• Pregnancy (see Section  2.17.4 for details)  
 
Necessity to withdraw the participant from the study will be assessed case-by- case by [CONTACT_122034] m edical monitor. 
[IP_ADDRESS] Tempora ry Discontinuation 
Treatment should be withheld temporarily  if any of the following conditions apply:  
• Occurrence of hypersensitivity after instillation of the eye drops  
• Rechallenge can be considered at the discretion of the investigator in consultation with 
the medical monitor  
 
The investigator may decide to temporarily  discontinue treatment for other reasons  if deemed 
appropriate for the safety  and well-being  of the participant.  The m edical monitor should be 
informed. 
2.14.11 Participant Discontinuation / W ithdrawal from the Study 
A participant may  withdraw from the study  at any time at his/her own request or  may be 
withdrawn at any time at the discretion of the i nvestigator for safety, behavioral, or 
compliance reasons.  This includes cases in which, in the investigator's opi[INVESTIGATOR_1649], continued 
participation in the study  would be harmful to the participant's  well-being. This is expected to  
be uncommon. 
Version: 5.[ADDRESS_253648] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  36 • At the time of discontinuing from the study, if possible, the final study visit should be 
conducted as early discontinuation visit, followed by [CONTACT_211697] -up as determined by 
[CONTACT_211698][INVESTIGATOR_119433]. See SoA for data to be collected at the time of study discontinuation and follow-up and for any further evaluations that need to be completed. 
• The participant will be permanently discontinued both from the study intervention and from the study at that time.  
• If the participant withdraws consent for disclosure of future information, the Sponsor 
may retain and continue to use any da ta collected before such a withdrawal of consent.  
 
2.14.[ADDRESS_253649] be taken if a participant fails to return to the clinic for a required  
study visit:  
• The site must attempt to contact [CONTACT_46342], counsel the participant on the importance of maintaining the assigned visit 
schedule, and ascertain whether or not the participant wishes to and/or should continue in the study. 
• Before a participant is deemed lost to follow -up, the investigator or designee must make 
every effort to regain contact [CONTACT_6635] (where  possible, 3 telephone calls and, 
if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods). These contact [CONTACT_13140]’s medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have withdrawn from the study.  
 
Discontinuation of specific sites or of the study as a whole are handled separately . 
2.15 Study A ssessments and Procedures  
Study procedures and their timing are summarized in the SoA ( Table  1). Protocol waivers or  
exemptions are not allowed.  
Immediate safety  concerns should be disc ussed with the sponsor immediately  upon 
occurrence or awareness to determine  if the participant should continue or discontinue study 
intervention. 
Version: 5.[ADDRESS_253650]  reasons for 
screening  failure,  as applicable.  
Procedures conducted as part of the participant’s routine clinical management (eg, blood  
count) and obtained before  signing of the ICF may be utilized  for screening  or BL purposes, 
provided the procedures met the protocol -specified  criteria  and were  performed  within  the 
time frame  defined  in the SoA.  
 
Version: 5.[ADDRESS_253651] Study: Schedule of A ctivities (Through Week 24 – Primary E ndpoint ) 
Study Procedure  Screening Visit 1  Baseline  (BL)  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  Visit 8a 
Week  -- 0 4 8 12 16 20 24 
Day (visit window)  -21 to -1 1 29 ± 
7 days  57 ± 
7 days  85 ± 
7 days  113 ± 
7 days  141 ± 
7 days  169 ± 
7 days  
Screening/Baseline  (BL) :          
Informed consent  X        
Inclusion/exclusion  X X       
Medical and ophthalmic history  X        
Demographics  X        
Randomization   
X       
Interval Medical Review :          
Review of concomitant medications  X X X X X X X X 
Continue study treatmentb   
X X X X X X  
Ocular Assessmentsn:          
Refraction and BCVA (ETDRS)  OU OU OU OU OU OU OU OU 
Slit lamp examination  OU OU OU OU OU OU OU OU 
Assessment of corneac OU OU OU OU OU OU OU OU 
Intraocular pressured  OU OU OU OU OU OU OU OU 
Indirect ophthalmoscopy  OU OU OU OU OU OU OU OU 
4-wide or 7 -field color fundus photography (mand atory)e OU OU SE SE OU SE SE OU 
SD-OCT (widefield if available)  OU OU SE SE OU SE SE OU 
OCTA (if available)  OU       
OU 
Wide field Fluorescein Angiographym OU       
OU 
Gonioscopy  OU       OU 
Version: 5.[ADDRESS_253652] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  39 Study Procedure  Screening Visit 1  Baseline  (BL)  Visit 2  Visit 3  Visit 4  Visit 5  Visit 6  Visit 7  Visit 8a 
Week  -- 0 4 8 12 16 20 24 
Day (visit window)  -21 to -1 1 29 ± 
7 days  57 ± 
7 days  85 ± 
7 days  113 ± 
7 days  141 ± 
7 days  169 ± 
7 days  
Non-Ocular Assessments:          
Physical examinationf X        
Vital signsg  X X X X X X X X 
Adverse eventsh  X X X X X X X X 
IP adherence reviewo   X X X X X X 
Laboratory Testing:i         
Hematology, blood chemistry, urinalysis, and HbA1cj,l  X       
X 
Pregnancy test, women of childbearing potentialk  serum  urine  urine  urine  urine  urine  urine  urine  
Abbreviations: BCVA: best corrected visual acuity; BL: baseline; ETDRS: Early Treatment Diabetic Retinopathy Study; HbA1c: glycosylated hemoglobin; OCTA: optical 
coherence tomography – angiography; OU: both eyes ; SD-OCT: spectral -domain optical coherence tomography; SE: s tudy eye . 
a Participants who are withdrawn from the study before Week 24/Visit [ADDRESS_253653], ASNV, or new onset or worsening CI-DME in the study eye, and before 
rescue treatment is given.  
f May be performed at Visit 1 or Visit 2, Including height, weight, and body temperature.  
g Vital signs (blood pressure and heart rate) will be measured after the participant has been sitting for [ADDRESS_253654] at each treatment visit starting at Visit 2 (Day 1); a negative urine pregnancy test is required before treatment is continued (randomized treatment, rescue 
treatment).  
l Refer to Appendix [ADDRESS_253655].  
Version: 5.[ADDRESS_253656] who meet all the  
inclusion criteria  and none of the exclusion  criteria  will be randomized to treatment with  
one of two dosing frequencies (BID/QID) of 5% OTT166  or vehicle control. During the 
treatment period, participants will be monitored  for AEs  and concomitant medication,  and 
undergo the assessments outlined  in the SoA (Section  2.15.1 ). 
The treatment period comprises Visits 2 to 8 ( BL/Day 1 to End of 
Treatment/Study/ Week  24), at which the primary  endpoint will be assessed. 
2.15.3 Blood Sampling 
Blood will be taken  at Visits 1 and 8 for laboratory assessments.  
• The amount of blood collected from each participant over the duration of the study, 
including any extra assessments that may be required, will be approximately 30 mL.  
• Repeat or unscheduled samples may be taken  for safety reasons or for technical issues 
with the samples.  
 
2.16 Efficacy A ssessments  
Planned time points for all efficacy  assessments are provided in the SoA  (Section  2.15.1). 
2.16.1 Ophthalmology A ssessments  
Ophthalmology examinations will be done for the study eye and/or both eyes as described in 
the SoA ( Section  2.15.1 ). 
2.16.2 Color F undus Photography (CFP) 
The anatomical  state of the retinal  vasculature will be evaluated  by [CONTACT_211699].  All digital CFP images need to be  taken by a 
certified technician  following an acquisition protocol for modified 7 -field stereoscopic color 
fundus photographs or 4-wide field imaging  of the  central reading center  at the visits 
indicated in the SoA ( Section  2.15.1 ). 
All CFPs will be transmitted to the  central reading center  for ETDRS  DRSS  (see Appendix 2) 
grading and storage. The images from the screening visit  of both eyes will be used as part of 
the eligibility  assessment regarding the severity  of diabetic  retinopathy. 
CFPs  may, in addition, be evaluated for additional, exploratory, endpoints. This may include 
assessment of microaneurysm turnover  (Nunes 2009) or measurement of diameters of  retinal 
vessels as described previously ( Lundberg 2013).  This may i nvolve transmission of CFP to 
additional central reading centers.   
Version: 5.[ADDRESS_253657] C orrected V isual A cuity (BCVA)  
Visual function will be assessed using  a modified  ETDRS  protocol starting  at 4 meters  
(AREDS 1999 ). Visual Acuity  examiners must be qualified to ensure consistent measurement  
of BCVA  and will be masked to study treatment assignment. 
2.16.4 Fluor escein Angiography (FA) 
The anatomical state of the retinal vasculature of the study  eye and the fellow eye  (only at 
BL and end of study [ EOS]) will be evaluated  by [CONTACT_62872] (widefield preferred) . All FAs will be 
conducted by a qualified  technician  following an acquisition  protocol of the central reading 
center.  The angiographic images will be  evaluated by a study ophthalmologist for individual 
safety decisions.  All FA images  will be archived electronically  at the site as part of the 
source documentation and sent to the central  reading center for evaluation  and storage on 
visits stated in the SoA  (Section  2.15.1). 
At screening , a standardized  set of FA images will be sent to  the central reading center for 
evaluation and eligibility  assessment.  
2.16.5 Optical C oherence Tomography (OCT) 
Structural OCT (widefield preferred) will be performed by [CONTACT_171119]. 
The specific device models accepted for  the study  will be defined by [CONTACT_178842]. OCTs will be performed  at every visit by  [CONTACT_211700]. OCTs will also be used for local safety  
assessment.  Newly  found clinically significant pathologies  should be reported  as AEs. All 
obtained images will be sent to the central reading  center  for evaluation, and central reading 
center data will be used for the final analysis . 
At screening , a standardized  set of OCT  images will be sent to the central reading center  for 
evaluation and eligibility  assessment.  Beside central subfield  thickness within the central 
1 mm (CST) and whole macular volume also the presence of center involving and non- center 
involving macular  edema will be assessed . SD-OCT will be also assessed for foveal contour 
and several exploratory outcome parameters and morphologic predictive biomarkers . 
2.16.6 Optical C oherence Tomography Angiography (OCTA) 
OCTA is optional  at sites that have an OCTA . The OCTA needs to be performed by a 
qualified technician following an acquisition protocol of the central reading center at Visits 1 and 8, as scheduled in the SoA  (Section  2.15.1) . The specifications of this OCTA can be 
found in th 
e acquisition protocol of the central reading center. Images obtained via OCTA 
will be sent to the Central Reading Center for evaluation.  Several quantitative a nd qualitative 
parameters, including the FAZ and area of nonperfusion, which have been shown to be associated with DR severity , will be assessed.  
Version: 5.[ADDRESS_253658] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  42 2.16.7 Slit Lamp B iomicroscopy ( Anterior and Posterior S egment)  
The slit lamp  examination (anterior and posterior segment)  will be performed  according to 
local  medical  practice  and applicable medical  standards at the site at every visit , as stated in 
the SoA ( Section  2.15.1 ). Abnormal findings are to be recorded  in the eCRF  as either  medical  
history  or AE, as applicable.  
2.16.8 Tonometry ( Intraocular P ressure (IOP) M easurement)  
IOP is to be measured at every visit with any locally  approved non-contact  [CONTACT_171125]. 
If there  is no non-contact [CONTACT_171126], applanation tonometry (Goldmann, 
Tonopen, or other  locally  approved alternatives) may be used. In any case,  where  both 
methods are available, the non-contact [CONTACT_171127]. In cases in which Goldmann 
applanation tonometry ( GAT ) is used, assessment of corneal health using fluorescein stain 
should be performed prior to tonometer applanation.  
The same method of  IOP measurement must be used thro ughout the study for each individual  
participant and should be performed at approximately the same time of day, if possible . 
Values, including time of day and measuring type, are to be recorded  in the eCRF.  
2.16.[ADDRESS_253659] (inclusive of participants who have 
vitreous hemorrhage or tractional retinal detachment believed to be due to PDR) and/or ASNV identified by [CONTACT_4718] (participants with neovascularization of the iris [at least 
2 cumulative clock hours], and/or definitive neovascularization of the iridocorneal angle) and/or CI- DME as defined in  Section 2.16.10 below.  
VTCs  are defined as occurrence of any  of the following AEs: 
• More than mild PDR  (DRSS 6 5 and above) 
• Iris neo -vascularization  
• CI-DME  
 
2.16.[ADDRESS_253660]  > 325 µm. 
The assessment  will be  continued after treatment discontinuation until end of study. 
Version: 5.[ADDRESS_253661] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  43 2.17 Safety A ssessments  
Safety will be assessed,  and TEAEs  recorded (as indicated) at every visit.  
2.17.1 Physical  Examination 
A physical examination (by [CONTACT_171128], palpation, auscultation) will be performed 
at Screening (Visit 1) as described in the SoA  (Section  2.15.1 ) by a physician at the study site 
and will cover at least the organs of the cardiovascular, respi[INVESTIGATOR_696],  and abdominal systems ; 
measuring body temperature will be included. Abnormal physical examination findings are recorded either as medical history or as AEs in the eCRF.  Body weight will be measured by a 
member of the investigator’s team . The body mass index ( BMI ) will be calculated by [CONTACT_211701] w eight and height.  
2.17.2 Vital S igns 
Pulse  rate and systolic / diastolic  blood  pressure will be measured  repeatedly  as outlined in 
the SoA ( Section  2.15.1 ). Blood pressure and heart rate will  be measured  in a supi[INVESTIGATOR_211659]  ≥ [ADDRESS_253662]. Blood pressure and heart rate should always be 
measured  before blood draws  when  scheduled  at the same time point. 
2.17.3 Clinical S afety  Laboratory A ssessments  
A lab assessment (hematology, blood chemistry, urinalysis, and HbA1c) will be performed at 
Screening  (Visit 1) and at Week 24 (Visit 8) as described in the SoA  (Section  2.15.1 ). Blood 
and urine samples will be taken . See Section  3.[ADDRESS_253663] be filed with the source documents. 
Abnormal  laboratory  findings associated with the underlying disease are not considered 
clinically  significant unless judged by [CONTACT_211702]'s  condition. 
All laboratory  tests with values considered clinically  significantly  abnormal during 
participation in the study  or within  one month after the last dose of study  intervention should 
be repeated  until the values return  to normal or BL or are no longer considered  clinically  
significant by [CONTACT_211703]. 
If such  values do not return to normal/ BL within a period of time judged reasonable by [CONTACT_1275], the etiology should be identified,  and the s ponsor notified.  
All protocol -required  
 laboratory  tests must be conducted in accordance with the laboratory 
manual and the SoA  (Section  2.15.1 ). If laboratory  values from non- protocol specified 
laboratory  tests performed at the institution’s  local laboratory  require a change in participant 
Version: 5.[ADDRESS_253664] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  44 management or are considered  clinically significant by [CONTACT_093] (eg, SAE or AE or 
dose modification), then the results must be  recorded. 
2.17.[ADDRESS_253665] is planned at Screening 
(Visit 1 ); during all other visits , urine tests will be performed. Dip stick urine pregnancy  tests 
allow the investigator to  take action  while the  participant is at site  in case of a positive test.  
If the urine pregnancy test is positive, the study medication should be discontinued 
immediately. The urine pregnancy test results should be however confirmed using a serum pregnancy test at a local lab b efore permanently discontinuing the participant from the study.  
2.18 Adverse E vents (AEs), Serious A dverse E vents (SAEs) , and O ther Safety 
Reporting  
The definitions of AEs and SAEs  can be found in Appendix 3 and will conform to the current 
Medical Dictionary for Regulatory Activities (MedDRA) standard . 
AEs will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, or 
the participant's legally authorized representative).  
The Investigator and any qualified  designees are responsible for detecting, documenting, and 
recording  events that meet  the definition  of an AE or SAE  and remain  responsible for 
following up  all A Es reported during the study until resolution or until the end of the study. 
2.18.1 Time  Period  and Frequency for C ollecting  AE and SAE  Information  
All AEs/SAEs will be collected from the  signing of the ICF until end of study. 
All SAEs will be recorded and reported  to the s ponsor or designee immediately and under no 
circumstance should this exceed  [ADDRESS_253666]-dose during the main treatment period until the 
end of study. 
Investigators are not obligated to actively  seek information on AEs  or SAEs after conclusion  
of the study participation/the  End-of-Study visit. However, if the i nvestigator learns of any 
AE/SAE,  including a death, at any time after a participant has been discharged from the 
study, and he/she considers the event to be reasonably related to the study intervention or 
study participation, the investigator must promptly  notify the sponsor. 
Version: 5.[ADDRESS_253667] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  45 2.18.2 Method  of D etecting  AEs and SAEs  
Care  will be taken  not to introduce bias when  detecting  AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant  is the preferred  method to inquire about AE 
occurrences.  
2.18.3 Follow- up of AEs and SAEs  
After the initial AE/SAE  report,  the investigator is required to proactively follow each  
participant  at subsequent visits/contacts.  All SAEs,  and AEs of special  interest (as defined  in 
Section  2.18.6), will be followed until resolution,  stabilization,  the event is otherwise 
explained, or the participant is lost to follow -up (as defined in Section  2.14.12).  Further  
information  on follow -up procedures is provided  in Appendix 4. 
2.18.4 Regulatory Reporting R equirements  for SAEs  
• Prompt notification by [CONTACT_211704] 
a study intervention under clinical investigation are met.  
• The sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The Sponsor will comply with country- specific regulatory requirements 
relating to safety reporting to the regulatory authority, Institutional Review Board (IRB)/ Independent Ethics Committee (IEC), and Investigators. 
• An investigator who receives an investigator safety report describing an SAE or other specific safety information (eg, summary or listing of SAEs) from the sponsor will review and then file it and will notify the IRB/IEC, if appropriate according to local requirements.  
• For all studies, investigator safety reports must be prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) according to local regulatory requirements and sponsor policy and forwarded to investigators as necessary. 
 
2.18.5 Pregnancy  
• Details of all pregnancies in female participants and, female partners of male participants 
will be collected after the start of study intervention and until the end -of study visit. 
• If a pregnancy is reported, the investigator will record pregnancy information on the 
appropriate form and submit it to the Sponsor within [ADDRESS_253668]. 
Version: 5.[ADDRESS_253669] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  46 • While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
• Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenita l anomalies, ectopic pregnancy) are considered SAEs, and will be reported as 
such. 
• The participant /pregnant female partner will be followed to determine the outcome of the 
pregnancy. The investigator will collect follow -up information on the 
participant/p regnant female partner and the neonate, and the information will be 
forwarded to the sponsor. 
• Any female participant who becomes pregnant while participating in the study will 
discontinue study intervention.  
 
2.18.[ADDRESS_253670] (AESI)  
AESI  must be reported to the Sponsor along the timelines  set for SAEs  (even though they 
may not be classified as serious), ie,  within  24 hours of the investigator ´s awareness, as 
described in  Appendix 4. 
AESI  are: 
• Hypersensitivity reactions. Symptoms of hypersensitivity reactions (allergic reactions) 
include: 
- Rash  
- Wheezing and difficulty breathing  
- Dizziness and fainting  
- Swelling around the mouth, throat or eyes 
- A fast pulse  
- Sweating  
 2.19 Pharmacokinetics  
In this study, no PK analysis will be done . 
Version: 5.[ADDRESS_253671] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  47 2.20 Statistical Considerations  
2.20.1 Statistical H ypotheses / Sample S ize D etermination  
This study is designed to evaluate the superiority of t wo doses of OTT166 (5 mg/day and 
10 mg/day) compared to vehicle control for the treatment of DR. For each dose within each 
endpoint, the null hypothesis is that there is no difference between OTT166 and vehicle 
control or the difference is in the direction of inferiority of OTT166 , and the alternative 
hypothesis is that there is a difference between OTT166  and vehicle control in the direction 
of superiority of OTT166. The vehicle control groups will be combined for all statistical 
analyses. No multiplicity adjustment is planned for this study.  
The study will enroll approximately  210 participants  randomized as described in 
Sectio n 2.14.3, 70 participants per group into each  treatment arm and 3 5 participants  per 
group into each matching vehicle control group and allowing for around 5% study attrition, 
aiming for at le ast [ADDRESS_253672] 2 steps from BL  on the DRSS at 
Week  24, completing 66 participants  per group (a ctive treatment BID, active treatment QID, 
combined vehicle control) through Week [ADDRESS_253673]  90% power to demonstrate 
that the active treatment is superior to vehicle control using a 1-sided alpha of 0.05, provided that the true treatment effect (active treatment efficacy rate minus vehicle control efficacy 
rate) is at least 0.[ADDRESS_253674]  for 
two proportions (continuity corrected). 
2.20.[ADDRESS_253675] improved by ≥  2 steps from b aseline at Week 24 as determined by c entral reading 
center assessment using DRSS . 
The secondary outcome measures are as follows:  
• Proportion of participants developi[INVESTIGATOR_211660] (DRSS 65 and above) at 
Week 24  
• Proportion of participants who develop ASNV at Week 24 
• Time to development of PDR worse than mild (DRSS 65 and above) 
• Proportion of participants who develop CI- DME at Week 24  
• Time to development of CI- DME  
Version: 5.[ADDRESS_253676] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  48 • Proportion of participants developi[INVESTIGATOR_211643] 24 
• Time to development of PDR w orse than mild (DRSS 65 and above) or CI- DME  
• Proportion of participants with change in DRSS steps at Week [ADDRESS_253677] worsening or improving by 1, 2, or ≥ 3 steps  
• Proportion of participants with mild PDR (DRSS score 61B) at baseline who regress to 
NPDR (DRSS score ≤ 53) by [CONTACT_10585] 24 
• Mean and median change in BCVA (ETDRS letters) from baseline to Week 24  
• Lines gained/lost in BCVA (±  5, 10, and 15 ETDRS letters) at Week 24 
• Mean and median change in AUC for chan ge in BCVA from baseline to Week 24 
• Mean and median change in CST from baseline to Week 24  
• AUC for change in CST from baseline to 24 weeks 
• Proportion of participants who met the objective rescue criteria as defined in 
Section  2.14.9. 
• Time to meet  objective rescue therapy  criteria  as defined in  Section  2.14.9. 
• Time to administration of rescue therapy. 
 
Exploratory outcomes measures  will include : 
• Change in Macular Volume (MV) from baseline to Week 24 for 1, 3, and 6 mm regions - MV will be defined as the sum of the 9 subfield measurements as provided by [CONTACT_211705]  
• Change in a rea of retinal non -perfusion from baseline to Week 24 seen on widefield 
fluorescein angiography (FA)  
• Proportion of participants with intact foveal avascular zone (FAZ) seen on widefield FA at Week 24  
• Optical coherence tomography angiography (OCTA) endpoints within the 6 mm area: 
- Change from baseline to Week 24 in FAZ area 
- Change from baseline to Week 24 in non- perfusion area  
- Change from baseline to Week 24 in vessel caliber  
- Change from baseline in i schemic Index  at Week 24 defined as total area of 
non-perfusion divided by [CONTACT_211706] (28.3 mm2) 
- Proportion of participants with new neovascularization at Week 24 
Version: 5.[ADDRESS_253678] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  49 - Proportion of participants with new IRMA at Week 24 
- Change in vessel density from baseline to Week 24 in the superficial an d deep layers 
 
2.20.3 Analysis S ets 
For purposes of analysis, the following analysis sets are defined: 
Table 2 Analysis Sets  
Analysis Set  Description  
Enrolled Set (ES) All participants who signed informed consent.  
Intent -to-Treat (ITT) 
Analysis Set  All randomized participants  who received at least one dose of study 
drug. Participants  will be included into the analysis as randomized.  
This corresponds to what is referred to in ICH E9 as the Full 
Analysis Set.  
Per-Protocol Set (PPS)  All ITT participants  without any major protocol deviations that 
could impact the primary endpoint.  
Safety Analysis Set  (SS) All participants  who receive at least one dose of study drug. 
Participants  will be included into the analysis based on treatment 
actually received, regardless of the treatment randomized.  
 
The ITT Analy sis Set will be used for all efficacy and BL  analyses except participant 
disposition which will be shown for the ITT Analysis Set and for the Safety Analysis Set if 
the two analysis sets differ . All randomized participants are expected to be dosed and any 
exceptions will be described  in the CSR. The PP set will be determined prior to database lock 
and will be used as supplementary analyse s of the primary endpoint. All safety analyses will 
be based on the Safety Analysis Set  (SS) . 
2.21 Statistical Analyses 
2.21.1 General Considerations  
Statistical analyses will include tabulations of summary data, inferential analyses, by [CONTACT_211707], and figures.  
All statistical tests will be one- sided and will be performed at the 5% level of significance, 
unless otherwise stated. The vehicle control group will be combined for all efficacy  analyses, 
and two-sided 90% confidence intervals will be presented. Frequency counts (n and 
percentages) will be made for each qualitative variable. Descriptive statistics (n, mean, standard deviation [ SD], median, minimum, and maximum) will be calculated for each 
quantitative variable, unless otherwise stated. All data will be summarized by [CONTACT_1570]. All safety  summaries and analyses will be based upon the Safety Analysis Set by 
[CONTACT_1570]  (i.e., vehicle control doses (5% BID, 5% QID), vehicle control combined, 
active OTT166 doses (5%  BID, 5% QID), and OTT166 combined). 
Version: 5.[ADDRESS_253679] (non- missing) measurement 
before dosing on Day 1. If any safety measurements are repeated after dosing on Day 1, then 
the last  (non- missing) value of any repeated measurements will be used in the descriptive 
statistics and in the calculation of changes from BL. 
2.21.2 Efficacy Analyses  
[IP_ADDRESS] Analysi s of the Primary Endpoint 
The primary estimand for the primary endpoint analysis is as follows:  
 Primary Estimand  
Treatment 
conditions of 
interest  OTT166 5 mg/day, OTT166 10 mg/day and matching vehicle control  
Participant  
Population  DR participants with Type 1 or Type 2 diabetes under adequate control 
(HbA1c ≤ 12.0%) who show typi[INVESTIGATOR_211661] 47, 53, and 61B, with BCVA ≥ [ADDRESS_253680] of  ≤ 325 μm, and a normal foveal contour.  
Endpoint  ≥ 2 steps improvement from BL in DRSS score at Week 24 . 
Population level 
summary  Difference in proportion of participants achieving ≥  2 steps 
improvement from BL in DRSS score at Week 24 between each 
OTT166 treatment group and the combined vehicle control group.  
Intercurrent events 
(ICEs) and 
strategies to ha ndle 
ICEs  a. Rescue treatment due to worsening DRSS level to 65 or higher prior to 
assessment of DRSS at Week 24  
Composite strategy (non -response)  
Death prior to DRSS assessment at Week 24  
Hypothetical strategy  
Use of rescue treatment for any other reason prior to DRSS assessment 
at Week 24  
Composite strategy (non -response)  
Premature discontinuation of study drug for any reason prior to DRSS assessment at Week 24  
Hypothetical strategy  
Study drug compliance <  75% through Week 24 
Treatment policy strat egy 
b. Study drug compliance between 75% to <  90% through Week 24  
Treatment policy strategy  
 ICE(s) with a composite variable strategy take priority over ICEs with 
other strategies. And ICEs with a hypothetical strategy take priority over 
ICEs with treatment policy strategy.  
 
Handling of missing DRSS response data at Week 24 in participants  without ICEs:  
• multiple imputation assuming missing at random (MAR)  
 
Version: 5.[ADDRESS_253681] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  51 Handling of DRSS response data at Week 24 missing after ICEs:  
• single imputation (non-response) when applying composite variable strategy 
• multiple imputation assuming MAR when applying hypothetical and treatment policy 
strategy  
 
Handling of DRSS response data at Week 24 observed after ICEs: 
• replaced by [CONTACT_105]-response (single imputation) in the analysis when applying composite 
variable strategy  
• replaced by [CONTACT_211708]  
• kept in the analysis when applying treatment policy strategy 
 
Comparison of the primary endpoint will be made between each dose group and the 
combined vehicle control group using a Mantel -Haenszel (MH) test of the difference in 
2 proportions stratified by [CONTACT_22055] (BL  DRSS score 47 or 53 or 
61B). The estimated MH risk difference will be summarized along with the 2-sided 90% CI 
using MH stratum weights  and the Sato variance estimator. The primary efficacy analysis 
will be performed on the ITT Analysis Set, while the PP set will be used as supplementary 
analyses. ICEs and missing data will be handled as described above. 
The primary efficacy analysis will also be performed by [CONTACT_211709], gender, and race to assess the consistency of the treatment effect. Additional subgroup analyses may also be conducted and will be described in the Statistical A nalysis Plan ( SAP). 
[IP_ADDRESS] Analyses
  of Secondary and O ther E fficacy Endpoints 
Estimands for the secondary endpoint analyses will be described in the SAP. 
The secondary endpoints involving proportions of participants will be analyzed using the 
same approach (MH test) as described for the primary efficacy analysis and based on the ITT. 
Time to event secondary endpoints will be analyzed using a stratified log -rank test adjusting 
for the randomization stratification factor. 
Continuous secondary endpoints involving change from BL  will be analyzed using an 
analysis of covariance (ANCOVA) model with BL measurement of the variable as a 
covariate and treatment group and the randomization stratification factor as fixed factors. The 
pair- wise comparisons of each OTT166 dose group versus combined vehicle contro l will be 
done in the ANCOVA model. Two -sided 90% confidence intervals for the difference of each 
OTT166 dose group minus combined vehicle control will be calculated. Additional details on 
Version: 5.[ADDRESS_253682] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  52 sensitivity analyses and missing data imputation of the secondary endpoints will be provided 
in the SAP.  
Analyses of exploratory imaging outcome measures will be described in the SAP . 
2.21.3 Safety Analyses  
All safety analyses will be performed on the Safety Analysis Set. No inferential statistics will be performed for safety va riables.  
2.21.4 Study Drug Exposure 
Exposure to study drug will be summarized using the ITT analysis Set and also  Safety 
Analysis Set.  The total number of doses administered and the duration of treatment for  each 
participant  will be summarized  using descriptive statistics by [CONTACT_1570] . 
2.21.5 Adverse Events 
AEs will be coded using MedDRA version 24.1 or higher and summarized by [CONTACT_70244] (SOC) and preferred term (PT). Analysis and reporting for AEs  will be based on 
TEAEs. A TEAE is defi ned as an AE occurring (onset date/time) at the time of or after 
dosing on Day 1. AEs  with missing start and/or end dates and/or times (if applicable) will be 
handled as described in the SAP.  
All TEAEs will be listed for each participant . Separate listings will be presented for TEAEs 
leading to discontinuation of study drug and treatment- emergent serious adverse events 
(TESAEs). Any AEs occurring between signing of ICF and dosing on Day 1 will be presented in a separate listing. All listings will be done by [CONTACT_131373], detailing verbatim, SOC, PT, start date, stop date (if resolved), intensity, seriousness, outcome, action taken with respect to study drug, and relationship to study drug. The AE onset will also be shown relative (in number of days) to the day of the first study drug 
administration.  
An overview of all TEAEs will be presented by [CONTACT_1570]. The overview will include the following: 
• Number and percentage of participants with TEAEs  
• Number and percentage of participants wit h drug- related TEAEs  
• Number and percentage of participants with TEAEs leading to discontinuation of study drug 
• Number and percentage of participants with TEAEs leading to study discontinuation 
• Number and percentage of participants with TESAEs  
• Number and pe rcentage of participants with drug -related TESAEs  
Version: 5.[ADDRESS_253683] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  53 • Number and percentage of participants with TESAEs leading to discontinuation of study  
drug 
• Number and percentage of participants with TESAEs leading to study discontinuation 
• Number and percentage of participants by [CONTACT_211710] (mild, moderate, severe) 
• Number and percentage of participants who experienced death from any cause  
• Number and percentage of participants with AESIs  
 
Summaries of TEAEs by [CONTACT_1570], SOC, and PT will be presented for the following: 
• All TEAEs  
• Ocular  TEAEs in the  Study Eye 
• Ocular TEAEs in the Fellow Eye  
• Non-Ocular  TEAEs  
• TEAEs leading to discontinuation of study 
• TEAEs leading to discontinuation of study drug 
• Drug -related TEAEs  
• All TESAEs  
• Ocular TESAEs in the Study Eye 
• Ocular TESAEs in the Fellow Eye  
• Non-Ocular TESAEs  
• TESAEs leading to discontinuation of study 
• TESAEs leading to discontinuation of study drug 
• Drug -related TESAEs  
• TEAEs by [CONTACT_2236] 
• AESIs  
• AESIs leading to discontinuation of study 
• AESIs leading to discontinuation of study drug 
 Additional details on AE summaries will be provided in the SAP . 
Version: 5.[ADDRESS_253684] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  54 2.21.6 Vital Signs  
Vital signs measurements will be listed by [CONTACT_211711]/unscheduled measurements. Descriptive statistics (n, mean, SD, 
minimum, median, maximum) will be provided by [CONTACT_211712] . 
2.21.7 Safety Laboratory Tests  
Laboratory safety assessments will be listed by [CONTACT_211713] , flags for any measurements that are outside the reference ranges , and any 
repeated/unsc heduled assessments. Descriptive statistics (n, mean, SD, minimum, median, 
maximum) will be provided by [CONTACT_211714] . A shift from BL  table describing shifts to out-of- normal range will be 
provided by [CONTACT_1570]. 
Urinalysis results will be listed by [CONTACT_211715], flags for any measurements that are outside the reference ranges, and any 
repeated/unscheduled assessments.  
The result s of pregnancy and H bA1c  testing will be listed for each participant. 
2.21.8 Other A nalyses  
Descriptive summaries of participant disposition and BL  characteristics (including 
demographic data and medical and ophthalmic history) will be presented by [CONTACT_1570]. In addition, a listing of participants  who discontinued from the study along with 
discontinuation reason will be provided. Listings of BL  characteristics and prohibited 
medications will also be provided.  
Protocol deviations will be listed and summarized by [CONTACT_211716].  
Medications will be coded using the W orld Health Organization Drug Dictionary (WHO DD) 
and listed by [CONTACT_211717] . A summary of concomitant medications by [CONTACT_211718].  
2.21.9 Interim  Analysis  
There are no interim analyses planned . 
Version: 5.[ADDRESS_253685] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  55 3 SUPPORTING D OCUMENTATION AND O PERATIONAL 
CONSIDERATIONS  
3.1 Appendix  1: Regulatory, E thical, and S tudy O versight C onsiderations 
3.1.1 Regulatory and Ethical Considerations 
• This study will be conducted in accordance with the protocol and with the following: 
- Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences International Ethical Guidelines  
- Applicable International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines  
- Applicable laws and regulations 
• The protocol, protocol amendments, ICF, IB, and other relevant documents (eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_6661]/IEC before the study is initiated. 
• Any amendments to t he protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants. Any substantial modification of the protocol will be submitted to the competent authorities as substantial amendments for approval, in accordance with ICH GCP and national and international regulations. 
• Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation except for changes necessary to eliminate an immediate 
hazard to study participants. 
• The investigator will be responsible for the following: 
- Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/IEC  
- Notifying the IRB/IEC of SAEs or other significant safety findings as required by [CONTACT_1744]/IEC procedures  
- Providing oversight of the conduct of the study at the site and adherence to requirements of ICH guidelines, the IRB/IEC, and all other applicable local regulations 
 
Version: 5.[ADDRESS_253686] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  56 3.1.2 Financial  Disclosure  
Investigators and sub-i nvestigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory  authorities. 
Investigators are responsible for providing information on financial interests during the study 
and for 1 year after completion of the study. 
3.1.3 Informed  Consent  Process  
• The Investigator or his/her representative will explain the nature of the study to the participants and answer all questions regarding the study. 
• Participants must be informed  that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of [ADDRESS_253687] requirements, where applicable, and the IRB/IEC or study center. 
• The medical record must include a statement that written informed consent was obtained before the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF. 
• Participants must be re -consented to the most current version of the ICF(s) during their 
participation in the study.  
• A copy of the ICF(s) must be provided to the participants.  
• Participants who are rescreened are required to sign a new ICF. 
 
3.1.4 Data  Protection  
• Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records, 
datasets or biological samples that are transferred to the Sponsor will contain the identifier only; participant names or any information which would make the participant identifiable will not be transferred.  
• The participant must be informed that his/her personal study -related data will be used by 
[CONTACT_9324]. The level o f disclosure must 
also be explained to the participant who will be required to give consent for their data to be used as described in the informed consent.  
• The participant must be informed that his/her medical records may be examined by 
[CONTACT_211719], by [CONTACT_6667]/IEC members, and by [CONTACT_9326]. 
 
Version: 5.[ADDRESS_253688] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  57 3.1.5 Committees  Structure  
[IP_ADDRESS] Central Reading C enter  
The digital  retinal images, OCT scans, fluorescence angiogr aphies,  and other images as 
applicable will be assessed by [CONTACT_211720].  Details pertaining to each 
imaging technique are as follows: 
• FP: DRS 4W/7M standard 2 -step plus adjudication 
• OCT: CI -DME, SRF/IRF, DRIL, TMV (1, 3, and 6mm) 
• FA: We will grade ONLY study eye 
• OCTA: vessel density, FAZ area, and nonperfusion 
 
[IP_ADDRESS] Steer ing C ommittee  
A steering committee consisting of experts in the field is created  to provide scientific  and 
operational recommendations to the study protocol and to potential day- to-day decisions in  
study conduct. The OcuTerra team and Steering Committee members will collaborate to 
ensure that the scope for the study is constrained to what is relevant with regard to the clinical indication, outcomes, and product under investigation, and most importantly, study participant safety. The  composition of the committee,  the functional roles,  and 
responsibilities  can be found in the  Steering Committee charter.  
3.1.6 Data  quality  Assurance 
• All participant data relating to the study will be recorded on printed or electronic CRF unless transmitted to the Sponsor or designee electronically (eg, laboratory data). The Investigator is responsible for verifying that data entries are accurate and correct by [CONTACT_1189].  
• All data objective and subjective will  be captured in the EDC and reported on. 
• Guidance on completion of CRFs will be provided in eCRF completion guidelines. 
• The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct acce ss to source data documents.  
 
Quality  tolerance limits (QTLs)  will be pre -defined in the  Integrated  Data Review Plan  to 
identify  systematic issues  that can impact  participant safety and/or reliability  of study results. 
These pre-defined parameters will be  monitored during the study and important deviations 
from the QTLs  and remedial actions taken will be summarized in  the clinical study  report.  
• Monitoring details describing strategy (eg, risk- based initiatives in operations and quality 
such as Risk Management and Mitigation Strategies and Analytical Risk -Based 
Version: 5.[ADDRESS_253689] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  58 Monitoring), methods, responsibilities, and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on- site monitoring) 
are provided in the Monitoring Plan. 
• The Sponsor or designee is responsible for the data management of this study including quality checking of the data. 
• The Sponsor assumes accountability for actions delegated to other individuals (eg, Contract Research Or ganizations).  
• Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by [CONTACT_1732] 15 years after study completion unless local 
regulations or institutional policies require a longer retention perio d. No records may be 
destroyed during the retention period without the written approval of the sponsor. No 
records may be transferred to another location or party without written notification to the 
sponsor. 
 
3.1.7 Source  Documents  
• Source documents provide evidence for the existence of the participant and substantiate 
the integrity of the data collected. Source documents are filed at the investigator’s site.  
• Data reported on the CRF or entered in the eCRF that are transcribed from so urce 
documents must be consistent with the source documents or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available. 
• Definition of what constitutes source data can be found in the Source Data Location List. 
• The investigator must maintain accurate documentation (source data) that supports the information entered in the CRF. 
• Study monitors will perform ongoing source data verification to confirm that data entered into the CRF by [CONTACT_1191], complete, and verifiable from source documents; that the safety and rights of participants are being protected; and that the study is being conducted in accor dance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements. 
 
3.1.8 Study  and Site Start and Closure 
[IP_ADDRESS] First A ct o
 f Recruitment  
The first act of recruitment is the  first participant  visit and will be the study start date.  
Version: 5.[ADDRESS_253690] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  59 [IP_ADDRESS] Study / S ite Termination  
The sponsor or  designee reserves the right to close the study  site or terminate the study  at any 
time for any reason at the sole discretion of the s ponsor . Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study  
supplies have been collected and a study- site closure visit has been performed. 
The investigator may initiate study- site closure at any  time, provided there is reasonable 
cause and sufficient notice is given  in advance of the intended termination.  
Reasons for the early  closure of a study  site by [CONTACT_3210] i nvestigator may include but are  
not limited to: 
For study termination: 
• Discontinuation of further study intervention development 
 
For site termination:  
• Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the sponsor's procedures, or GCP guidelines 
• Inadequate or no recruitment (evaluated after a reasonable amount of time) of participants by [CONTACT_093] 
• Total number of participants included earlier than expected.  
 
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the  
investigators, the IECs/IRBs, the regu latory authorities, and any contract research  
organization(s) used in the study of the reason for termination or suspension, as specified by  
[CONTACT_211721].  The investigator shall promptly inform the  participant 
and should assure appropriate  participant therapy  and/or follow -up. 
3.1.9 Publication P olicy  
• The results of this study may be published or presented at scientific meetings. If this is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the Sponsor 
before submission. This allows the sponsor to protect proprietary information and to provide comments. 
• The sponsor will comply with the requirements for publication of study results. In accordance with standard editorial and ethical practice, the sponsor wi ll generally support 
publication of multicenter studies only in their entirety and not as individual site data. In this case, a coordinating investigator [INVESTIGATOR_12992].  
Version: 5.[ADDRESS_253691] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  60 • Authorship will be determined by [CONTACT_14346].  
 
Version: 5.[ADDRESS_253692] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  61 3.2 Appendix  2: ETDRS Final Retinopathy Severity Scale  
Table  3 ETDRS  Final R etinopathy  Severity  Scale (for Individual  Eyes) 
Level Severity Definition 
10 DR absent Microaneurysms and other characteristics absent 
12 ٭ Non-DR abnormalities 
14 ٭ DR questionable 14A HE definite; microaneurysms absent 
14B SE definite; microaneurysms absent 
14C IRMA definite; microaneurysms absent 
14Z Venous loops >  D/1; microaneurysms absent 
15 ٭ DR questionable Hemorrhage(s) definite; microaneurysms absent 
20 Microaneurysms only Microaneurysms definite, other characteristics absent 
35† Mild NPDR 35A Venous loops ≥ D/1 
35B SE, IRMA, or VB = Q 
35C Retinal hemorrhages present 
35D HE ≥ D/1 ( < STD 3 in any field ) 
35E HE ≥ M/1 ( ≥ STD 3 in any field ) 
35F SE ≥ D/1 ( any definite ) 
[ADDRESS_253693] 43A H/Ma = M/4-5  (> STD 1(4+ fields) -OR- ≥ STD 
2A (1 f ield) )  
43B IRMA = D1-3  (any definite < STD 8A ) 
[ADDRESS_253694] 47A Both L43 characteristics 
47B IRMA = D/4-5  ( < STD 8A )  
47C H/Ma = S/2-3  ( < STD 2B )  
47D VB = D/[ADDRESS_253695] 53A ≥ 2 of the L47 characteristics 
53B H/Ma ≥ S/4-5  ( ≥ ST D 2A in 4+ fields or ≥ 2B in any 
field )  
53C IRMA ≥ M/1 ( ≥ STD 8A )  
53D VB ≥ D/2-3  or S1 ( ≥ STD 6 in 2+ fields or ≥ 6B in any 
field)  
53E Very Severe NPDR 53E ≥ [ADDRESS_253696] 61A FPD and/or FPE only (regressed PDR)  
61B NVE < ½ DA in ≥ [ADDRESS_253697] 65A NVE ≥ M/1 ( ≥ ½ DA in ≥ 1 field)  
65B NVD = D ( < STD 10A ) ; and VH and PRH = A or Q 
65C VH or PRH = D ( < 1 DA) and NVE < M (< ½ DA ) and 
NVD absent  
Version: 5.[ADDRESS_253698] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  62 71/[ADDRESS_253699] 71A VH or PRH ≥ M/1 ( ≥ 1 DA )  
71B NVE ≥ M/1 ( ≥ ½ DA 1 field ) and VH o r PRH ≥ D/1 
( any )  
71C NVD = D ( < STD 10A ) and VH or PRH ≥ D/1 ( any ) 
71D NVD ≥ M ( ≥ STD 10A ) 
75 NVD ≥ M ( ≥ STD 10A) and VH or PRH ≥ D/1 (any) 
[ADDRESS_253700]: fundus partially 
obscured, center of macula attached NVD = cannot grade, or NVD < D and NVE = cannot grade 
in ≥ 1 field and absent in all others; and retin al detachment at 
center of macula < D  
[ADDRESS_253701]: posterior fundus 
obscured, or center of macula 
detached  85A VH = VS (obscuring) in Field 1 or 2 85B Retinal 
detachment at center of macula = D (present)  
90 Cannot grade, even for 81 or 85 
Abbreviations:  DR = diabetic retinopathy; NPDR = nonproliferative DR; PDR = proliferative DR; HE = hard 
exudates; SE =  soft exudates; IRMA = intraretinal microvascular abnormalities; VB = venous beading; 
H/Ma  = hemorrhages/microaneurysms; NVE = new vessels elsewhere; NVD = new vessels on or adjacent to 
optic disc; VH = vitreous hemorrhage; PRH = preretinal hemorrhage  
Severity categories are of the form (maximum severity/extent), where maximum severity can be absent (A), 
questionable (Q), definitely present (D), moderate (M), severe (S), or very severe (VS), and extent is the 
number of photographic fields at that severity level.  For example, M/2 -3 means there are two or three fields 
from fields 3 to 7 with moderate severity, and none with higher severity.  
٭ Levels 12, 14, and 15 are not considered separate steps in the scale, but are pooled with level 10 or 20 (or exclud ed). 
† NPDR levels 35 and above all require presence of microaneurysms.  
Version: 5.[ADDRESS_253702] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  63 3.3 Appendix  3: Clinical Laboratory T ests 
•The tests detailed in Section  2.15.1 and the table below ( Table  4) will be performed
locally at the study site and sent to the central laboratory for analysis with the exception
of urine pregnancy tests, which will be performed and analyzed locally at the site.
•Additional tests may be performed at any time during the study as determined necessary
by [CONTACT_11006].
Inves
tigators must document their review of each laboratory  safety  report.  
The laboratory  parameters to be analyzed  are defined below in Table  4. The time points of 
analysis are at Screening and EOS  as defined in the SoA (Section  2.15.1). All labs are 
expected to be random (non- fasting). 
Additional local laboratory tests may be performed  as deemed  appropriate by [CONTACT_737]  
(eg, in case of signs of any  toxicity ). 
Table  4 Clinical Laboratory Tests  
CHEM 20  CBC  Urinalysis  
Glucose  Hemoglobin  Sp. Gravity (SG)  
Sodium  Hematocrit  pH 
Potassium  MCV  Leukocyte esterase  
Carbon dioxide  MCH  Nitrites  
Chloride  Red Cell Count  Hemoglobin  
BUN  White Cell Count  Protein (Total)  
Creatinine  Neutrophils (%)  Glucose  
Calcium  Total Lymphs (%)  Ketones  
Iron Monocytes (%)  Urobilinogen  
Albumin  Eosinophils(%)  Bilirubin  
Total protein  Basophils (%)  
ALP  Neutrophils (Abs)  
ALT (SGPT)  Total Lymphs (Abs)  
AST (SGOT)  Monocytes (Abs)  
LDH  Eosinophils(Abs)  
GGT  Basophils (Abs)  
Bilirubin (total)  Platelets  
Uric acid  
Amylase  
Lipase  
Version: 5.[ADDRESS_253703] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  64 3.4 Appendix  4: AEs and SAEs: Definitions and P rocedures for Recording, 
Evaluating, Follow- up, and R eporting  
 
3.4.1 AE Definition  
• An AE is any untoward medical occurrence in a clinical study participant, associated with 
the use of study intervention, whether or not considered related to the study intervention. 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) associated with the use of study intervention. 
 
3.4.2 Events M eeting the AE D efinition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, radiological scans, vital signs measurements), including 
those that worsen from BL, considered clinically significant in the medical and scientific judgment of the Investigator (ie, not related to progression of underlying disease). 
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition. 
• This includes progression of DR New conditions detected or diagnosed after study intervention administration even though it may have been present before the start of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected intervention -intervention 
interaction.  
• Signs, symptoms, or the clinical sequelae o f a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported rega rdless of sequelae.  
 
 
3.4.3 Events NOT M eeting the AE D efinition  
• Any clinically significant abnormal laboratory findings or other abnormal safety assessments which are associated with the underlying disease, unless judged by [CONTACT_211722]’s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant’s condition. 
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE. 
Version: 5.[ADDRESS_253704] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  65 • Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]). 
• Anticipated day- to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
 
An SAE is defined as any AE that, at any dose:  
a. Results in death  
b. Is life- threatening  
- The term 'life -threatening'  in the definition of 'serious' refers to an event in which  the 
participant  was at risk of death  at the time of the event. It does not refer to an event, 
which  hypothetically might have caused death, if it were more  severe.  
c. Requires inpatient hospi[INVESTIGATOR_1081]  
- In general, hospi[INVESTIGATOR_211662]  (usually 
involving at least an overnight stay)  at the hospi[INVESTIGATOR_211663]/or treatment  that would not have  been  appropriate  in the physician’s  
office or outpatient setting. Complications  that occur  during hospi[INVESTIGATOR_85299]. 
If a complication  prolongs hospi[INVESTIGATOR_211664],  the 
event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary, the AE should be considered  serious.  
- Hospi[INVESTIGATOR_21358] a pre-existing condition that did not worsen  
from BL is not considered an AE. 
d. Results in persis tent or significant disability/incapacity  
- The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.  
- This definition  is not intended to include experiences of relatively  minor  medical  
significance such as uncomplicated  headache,  nausea,  vomiting, diarrhea, influenza, 
and accidental trauma (e g, sprained ankle) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption. 
e. Is a congenital anomaly/birth defect 
f. Other  situations:  
- Medical  or scientific  judgment should be exercised  by [CONTACT_941] I nvestigator  in deciding 
whether SAE  reporting is appropriate in other situations such as significant medical 
events that may  jeopardize the participant or may  require medical or surgical 
intervention to prevent one of the other outcomes listed in the above definition. These 
events should usually be considered serious. 
- Examples of such events include invasive or malignant cancers,  intensive treatment 
for allergic bronchospasm, blood dyscrasias,  convulsions, or development of  
intervention dependency or intervention abuse.  
Version: 5.[ADDRESS_253705] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  66 3.4.4 Recording  and Follow- up of AE and / or SAE  
AE and SAE recording  
• When an AE/SAE occurs, it is the responsibility  of the I nvestigator to review all 
documentation ( eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) 
related to the event.  
• The Investigator will then record  all relevant  AE/SAE  information.  
• It is not acceptable for the Investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to  Sponsor in lieu of completion of the AE/SAE CRF page.  
• There may  be instances when  copi[INVESTIGATOR_211665]. In  this case, all participant identifiers, with the exception  of the participant 
number, will be redacted on the copi[INVESTIGATOR_211666].  
• The Investigator will attempt to establish  a diagnosis of the event  based  on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
 
3.4.5 Assessment of Intensity  
• The I nvestigator will make an assessment of intensity  for each AE and SAE reported 
during the study and assign it to 1 of the following categories: 
• Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal discomfort and 
not interfering with everyday activities.  
• Moderate: An event that causes sufficient discomfort  to interfere with normal everyday 
activities.  
• Severe: An event that prevents normal everyday activities. An AE that is  assessed as 
severe should not be confused with an SAE.  Severe is a category  utilized for rating the 
intensity  of an event; and both AEs and SAEs can be assessed as severe.  
• An event is defined as ‘serious’ when it meets at least 1  of the predefined outcomes as 
described in the definition of an SAE, NOT when it i s rated as severe.  
 3.4.6 Assessment of Causality 
• The Investigator is obligated  to assess the relationship  between  study intervention and 
each occurrence of each AE/SAE.  
• A “reasonable possibility” of a relationship  conveys that there  are facts, evidence, and/or 
arguments  to suggest a causal  relationship, rather than a relationship  cannot be ruled  out. 
Version: 5.[ADDRESS_253706] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  67 • The Investigator will use clinical  judgment to determine  the relationship. 
• Alternative causes, such as underlying disease(s),  concomitant therapy, and other  risk 
factors, as well as the temporal relationship of the event to study  
• intervention administration  will be considered and investigated. 
• The I nvestigator will also consult the Investigator’s  Brochure (IB) and/or Product 
Information,  for marketed products, in his/her  assessment.  
• For each AE/SAE, the I nvestigator  must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may  be situations in which an SAE has occurred, and the Investigator has minimal 
information  to include in the initial report to Sponsor. However,  it is very important 
that the I nvestigator always make an assessment of causality for every  event  before 
the initial transmission  of the SAE data to  Sponsor. 
• The I nvestigator may  change his/her opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality assessment.  
• The causality  assessment is one of the criteria used when determining regulatory 
reporting requirements.  
 
 
3.4.7 Follow- up of AEs and SAEs  
• The Investigator is obligated  to perform or arrange  for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by [CONTACT_211723]/or causality  of the AE or SAE as fully  as possible.  This may  
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.  
• New or updated information will be recorded in the originally  submitted documents. 
• The I nvestigator will submit any  updated SAE data to the Sponsor  within  24 hours of 
receipt  of the information.  
 
3.4.8 Reporting of SAEs  
SAE reporting to Sponsor via an electronic data collection tool The primary  mechanism for reporting an SAE to  Sponsor  will be the electronic data 
collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data 
transmission (see next section) to report the event within 24 hours.  
Version: 5.[ADDRESS_253707] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  68 • The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
• After the study is completed  at a given site, the electronic data collection tool. 
• will be taken off-line to prevent the entry of new data or changes to existing data. 
• If a site receives a report of a new SAE from a study participant or receives updated data on a previously reported SAE after the electronic data collection tool has been taken 
off-line, then the site can report this information on a paper SAE form (see next section) 
or to the Sponsor’s Medical Monitor by [CONTACT_756]. 
• Contacts for SAE reporting can be found in the Investigator Site File. 
 
SAE reporting to Sponsor via paper data collection tool 
 
• Email transmission of the SAE paper data collection tool is the preferred method to 
transmit this information to the Sponsor.  
• In rare circumstances and if email transmission is not feasible, notification by [CONTACT_13186] a copy of the SAE data collection tool sent by [CONTACT_22855].  
• Initial notification via telephone does not replace the need for the Investigator to complete and sign the SAE data collection tool within the designated reporting time frames.  
• Contacts for SAE reporting can be found in the Investigator Site File. 
 
Version: 5.[ADDRESS_253708] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  69 3.5 Appendix  5: Contraceptive Guidance and C ollection of Pregnancy 
Information  
3.5.[ADDRESS_253709]-menopausal 
unless permanently sterile (see below).  
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of study intervention, additional evaluation should be considered. 
Women in the following categories are not considered women of childbearing potential a. Premenarchal  
b. Premenopausal female with 1 of the following:  
• Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy  
 
For individuals with permanent infertility  due to an alternate  medical  cause other than the 
above, ( eg, M ullerian agenesis, androgen insensitivity),  Investigator discretion should be 
applied to determining study entry. 
Note:  Documentation can come from  the site personnel’s: review  of the participant’s  medical 
records, medical examination, or medical history interview.  
Females on HRT  and whose menopausal  status  is in doubt will be required to use one of the 
non-estrogen hormonal highly effective contraception methods if they  wish  to continue their 
HRT  during the study. Otherwise, they  must discontinue HRT to allow confirmation  of 
postmenopausal status before study enrollment.  
3.5.[ADDRESS_253710] agree  to use condoms. 
This applies from the time of ICF signature [CONTACT_171160]. 
Version: 5.[ADDRESS_253711] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  70 Table  5 Highly  Effective C ontraception M ethods  
• Implantable hormonal contraception associated with inhibition of ovulation  
• Intrauterine device  
• Intrauterine hormone -releasing  system  
• Bilateral tubal occlusion  
• Hormonal contraception with inhibition of ovulation, either estrogen  and progestogen containing 
or progesterone -only 
• Vasectomized partner if sole sexual partner 
• Sexual abstinence  
Modified from: Clinical Trial Facilitation Group 2014: Recommendations related to contraception and 
pregnancy testing in clinical  trials  (CTFG 2014).  
 
3.5.3 Collection of P regnancy I nformation  
Male participants with  partners who become pregnant  
• The Investigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This applies only to male participants who receive study intervention. 
• After obtaining the necessary signed informed consent from the pregnant female partner directly, the Investigator will record pregnancy information on the appropriate form and 
submit it to the Sponsor within 24 hours of learning of the partner’s pregnancy. The female partner will also be followed to determine the outcome of the pregnancy. Information on the status of the mother and child will be forwarded to the Sponsor. Generally, the follow-up will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless of fetal status (presence or absence of anomalies) or indication for the procedure.  
 
Female participants who become pregnant  
• The Investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study. The initial information will be recorded on the appropriate form and submitted to the Sponsor within 24 hours of learning of a participant's pregnancy. 
• The participant will be followed to determine the outcome of the pregnancy. The Investigator will collect follow -up information on the participant and the neonate and the 
information will be forwarded to the Sponsor. Generally, follow -up will not be required 
for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of 
Version: 5.[ADDRESS_253712] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  71 pregnancy will be reported, re gardless of fetal status (presence or absence of anomalies) 
or indication for the procedure. 
- While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
- A spontaneous abortion (occurring at < 22 weeks gestational age) or still birth (occurring at > 22 weeks gestational age) is always considered to be an SAE and will be reported as such.  
• Any post- study pregnancy related SAE considered reasonably related to the study 
intervention by [CONTACT_211724] 4. While the Investigator is not obligated to actively seek this information in 
former study participants, he or she may learn of an SAE through spontaneous reporting. 
• Any female participant who becomes pregnant while participating in the study will discontinue study intervention. 
 
Version: 5.[ADDRESS_253713] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  72 4 REFERENCES  
Aiello LM, Berrocal J, Davis MD, et al. The Diabetic Retinopathy Study. Arch Ophthalmol . 
1973;90(5):347–348. 
AREDS. The Age -Related Eye Disease Study (AREDS): design implications. AREDS report 
no. 1. Control Clin Trials . 1999 Dec;20(6):573-600. 
Askew  BC, Furuya  T, Edwards  DS. Ocular Distribution and Pharmacodynamics of SF0166, 
a Topi[INVESTIGATOR_211667] αvβ3 Integrin Antagonist, for the Treatment of Retinal Diseases. J 
Pharmacol Exp Ther . 2018 Aug;366(2):244- 250.  
Brucker AJ , Qin H, Antoszyk AN, et al, ( Diabetic Retinopathy Clinical Research Network ). 
Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol . 2009;127(2):132-40. 
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet . 2010;376(9735):124-36. 
CTFG. Recommendations related to contraception and pregnancy testing in clinical trials. Available on: https://www.hma.eu/fileadmin/dateien/Human_Medicines/01 - 
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf.15Sep.2014. 
ETDRS report number 10. Grading diabetic retinopathy from stereoscopic color fundus 
photographs --an extension of the modified Airlie House classification. Early Treatment 
Diabetic Retinopathy Study Research Group. Ophthalmology . 1991;98([ADDRESS_253714]):[ADDRESS_253715], Podgor MJ, Davis MD. Macular edema in Diabetic Retinopathy Study patients. Diabetic Retinopathy Study Report Number 12. Ophthalmology . 1987;94(7):754-
760. 
Friedman SM, Almukhtar TH, Baker CW, et al. Topi[INVESTIGATOR_211668]. Retina . 2015;35(5):944-956. 
Lechner J, O'Leary O, Stitt AW. The pathology associated with diabetic retinopathy. Vision Res. 2017;139:7-14. 
Lundberg K, Kawasaki R, Sjølie AK, Wong TY, Grauslund J. Localized changes in retinal vessel caliber after focal/grid laser treatment in patients  with diabetic macular edema: a 
measure of treatment response? Retina . 2013;33(10):2089- 95. 
Nunes S, Pi[INVESTIGATOR_6054] I, Rosa A, Duarte L, Bernardes R, Cunha- Vaz J. Microaneurysm Turnover Is 
a Biomarker for Diabetic Retinopathy Progression to Clinically Significant M acular Edema: 
Findings for Type 2 Diabetics with Nonproliferative Retinopathy. Ophthalmologica . 
2009;223(5):292-7.  
Version: 5.[ADDRESS_253716] of baseline Diabetic Retinopathy Severity 
Scale scores on visual outcomes in the VIVID -DME and VISTA -DME studies. Br J 
Ophthalmol . 2018;102(7):954 -958.  
Wang W, Lo ACY. Diabetic Retinopathy: Pathophysiology and Treatments. Int J Mol Sci. 2018;19(6):1816. 
Version: 5.[ADDRESS_253717] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  74 SPONSOR SIGNATURES  
Study Title:  OTT166 -201 A Phase 2 Randomized, Double -Masked, 
Vehicle- Controlled, Multicenter Study to Evaluate the Safety and 
Efficacy of OTT166 Ophthalmic Solution in the Treatment of 
Diabetic Retinopathy (DR)  
Study Number:  OTT166 -201 
Version Number:  V5.[ADDRESS_253718] to critical review and has been approved by [CONTACT_103]. The following personnel contributed to writing and/or approving this protocol: 
S
igned: Date:  
David J. Tanzer, MD  
OcuTerra Therapeutics 
Chief Medical Officer  
October 11, 20 23
Version: 5.[ADDRESS_253719] Study  CONFIDENTIAL  
October  10, 2023 OcuTerra Therapeutics  75 INVESTIGATOR’S SIGNATURE  
[CONTACT_2759]:  OTT166 -201 A Phase 2 Randomized, Double -Masked, 
Vehicle- Controlled, Multicenter Study to Evaluate the Safety and 
Efficacy of OTT166 O phthalmic Solution in the Treatment of 
Diabetic Retinopathy (DR)  
Study Number:  OTT166 -[ADDRESS_253720] the described study in compliance with Good Clinical Practices (GCP), the ethical principles contained within the Declaration of Helsinki, this protocol, and all applicable regulatory requirements, including [LOCATION_002] (US) Food and Drug Administration (FDA) 21 Code of Federal Regulations (CFR) 312 
     
Study Center:  
 
          
Principal Investigator:  
(Print Name) 
 
          
Signature:  
       [CONTACT_1782]:     
 